Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 
INTRODUCTION
Breast cancer is a common disease in women but the causes are still largely unknown. There is considerable evidence to suggest that genetic factors play an important role in causing breast cancer. In the last decade considerable progress has been made and two major breast cancer genes, BRCA1 and BRCA2, have been identified (Rahman and Stratton, 1998) . These genes carry a high risk of breast cancer but only account for a very small proportion of breast cancer families. Weaker genes are likely to be involved in the majority of familial breast cancers and some breast cancer cases without a family history of the disease, but relatively few have been Our aim is to identify and characterize the genetic factors that increase the chance of breast cancer occurring. We have collected clinical information and samples from over 2000 breast cancer families. We first characterized these for the known breast cancer genes, BRCA1
and BRCA2, with particular emphasis on clarifying the contribution and nature of large rearrangements of these genes, which have been identified in some familial breast cancer pedigrees and which are not identifiable by gene sequencing. We have then proceeded to try to identify new genes, by comparing the frequency of genetic factors in these cases with control women without breast cancer. Initially, we have been focusing on analyzing genes that we suspect may have a role in breast cancer, because they are related to known breast cancer genes. This has resulted in our identification of four, intermediate penetrance genes, ATM, CHEK2, BRIP1, PALB2, which confer risks of 2-3 fold (refs -references submitted with last years report). Within the last few years we have also been involved in large-scale international studies to use genome-wide tag SNP analyses of 100s of thousands of common variants in breast cancer cases and controls to identify variants associated with very low risks (<1. controls. This did not provide conclusive evidence that any are associated with breast cancer, confirming the emerging impression that one cannot predict which variants are associated with breast cancer and that whole-genome (rather than targeted) strategies will be required to maximize the harvest of breast cancer susceptibility alleles (Wellcome Trust Case-control Consortium 2008, see attached paper).
Over the future course of the study we therefore plan to extend the genome-wide tag SNP approach in larger series to identify further common, low penetrance susceptibility alleles and we will use emerging whole genome-resequencing technologies to analyze every gene. If we find any variants that are more frequent in breast cancer cases than controls, it suggests that they may be involved in causing breast cancer. We will evaluate these variants in further cases and controls to prove an association with breast cancer and to define the risk and outcomes of carrying the genetic variant(s).
BODY
As part of the program of work we defined five tasks. The progress towards the tasks is outlined in detail below.
Task 1: Evaluate the contribution of BRCA1 and BRCA2 exonic deletions and duplications to breast cancer susceptibility.
We have undertaken analyses for genomic exonic deletions and duplications of BRCA1 and BRCA2 in 1500 familial breast cancer cases from separate pedigrees in which mutations of these genes have been excluded. We use a simple, cost-effective copy number analysis technique, multiplex ligation-dependent probe amplification (Schouten et al. 2002; Bunyan et al. 2004 ).
This analysis has resulted in the identification of genomic duplication / deletion abnormalities in ~ 4% breast cancer families.
Our analyses have demonstrated that:
 MLPA is a cheap, high-throughput and robust technique for copy-number variations, in most situations.
 MLPA should be undertaken in addition to sequencing in all breast cancer families.
 Certain probes show inter-assay variability. We have informed the manufacturers of this and the probes have been replaced.

Single exon deletions must be further investigated and confirmed -firstly by sequencing to exclude a small exonic mutation under the probe, and if this is normal, by another copynumber assay such as quantitative PCR.
The clinical features and risks of cancer are the same for families with genomic deletions / duplications as for intragenic mutations.
This strategy is being followed in diagnostic services throughout the UK and in many places internationally.
This project is now complete. We have altered the design of our study to take advantage of technical improvements, more competitive pricing and an international consortium of ~ 30,000 cases and 30,000 controls (Breast Cancer Association Consortium, BCAC) that we are part of and that has been set-up to evaluate variants. This has allowed us to combine Tasks 2 and Task 4 (Identification genomewide familial case-control analyses) as follows:
 We have identified 114 non-synonymous coding single nucleotide polymorphisms (SNPs) in DNA repair genes through our sequencing of DNA repair genes in 96 BRCA1/2 negative cases Probes were successfully designed for 92 of these.
We included these 92 probes in an array that also included 14,389 non-synonymous coding SNPs that were available from the databases.
We analysed the 14471 SNPs in 864 familial breast cancer cases and 1498 controls.
These results have identified a number of interesting candidates that we are now pursuing.
The overall results of these analyses combined with similar analysis in three other diseases has now been published (Wellcome Trust Case-Control Consortium, 2008)
We were part of a similar designed complementary study using genome-wide tag SNPs rather than non-synonymous SNPs (i.e. targeting common variation rather than potentially functional variants) in which successfully identified 5 new common breast cancer susceptibility variants. This study was undertaken using a 3 stage approach, initiating with . Four of the SNPS identified occur in plausible causative genes (FGFR2,
TNRC9, MAP3K1 and LSP1).
Full results were published in Nature, , attached) and we provide here a summary of the per allele odds ratios by age at breast cancer diagnosis in stage 3, for the five independent SNPs reaching p<10 -7. SNP rs number <40 

As the common low penetrance breast cancer susceptibility variants appear to be embodied in non-coding rather coding variants we have altered the design of this experiment. We next plan to undertake a larger scale genome-wide tag SNP search (that we are leading) using 4000 familial breast cancer cases and 4000 controls. This is 10x
larger than the Easton et al experiment and will be completed in the next 18 months.
Task 3. Characterise the histopathology and immunohistochemistry of familial breast cancer. Months 12-36: a) Perform detailed pathological review and immunohistochemical analysis of at least 150 non-BRCA1/2 familial breast cancers. b) Compare pathology and immunohistochemistry of non-BRCA1/2 familial cancers, BRCA1 cancers, BRCA2 cancers and unselected breast cancers. c) Define pathological / immunohistochemical characteristics of non-BRCA1/2 cancers which may allow stratification into subgroups that facilitate identification of underlying susceptibility alleles.
 Within the last year we have identified three new breast cancer predisposition genes (see below). We are therefore focusing on obtaining and characterizing tumors from mutation carriers of these new genes.

We are undertaking detailed pathology, immunohistochemistry and loss of heterozygosity analyses to define the tumor characteristics associated with the ATM, BRIP1 and PALB2 mutations. We have undertaken the first phase of this task as outlined above under Task 2. We have been able to increase the size of the study at the same cost, greatly improving the power to detect true associations, due to methodological advancements. The results of the study are now published and we are focusing on analyses of tag SNPs as outlined above.
Task 4. Perform genome-wide familial case-control analyses of non-synonymous coding
This project is complete. attached paper). This raised the possibility that monoallelic PALB2 mutations might be associated with increased risk of breast cancer, which we were able to demonstrate using our familial case-control strategy , paper sent in last years report). 
2)
We have analysed 14,471 non-synonymous coding SNPs in 864 familial BRCA1/2-negative breast cancer cases and 1498 controls (WTCCC and TASC, 2007).
3)
We have participated in an international genome-wide tag SNP association study that has identified 5 low-penetrance breast cancer predisposition alleles (Easton et 
REPORTABLE OUTCOMES
We have published four research papers and one Perspective in Nature Genetics, one paper in Nature, a review in Human Molecular Genetics and a review in Oncogene.
CONCLUSION
We have had another exceptionally productive year. We have made substantial progress towards our goals and emerging technologies promise further advances and will allow us to considerably improve the power of the studies at similar cost. We are ensuring that our unique sample resources are being used for maximum benefit by participating in International consortia analyses as well as undertaking our own research. We anticipate that rest of the programme will proceed on course and are hopeful of further discoveries. Breast cancer exhibits familial aggregation, consistent with variation in genetic susceptibility to the disease. Known susceptibility genes account for less than 25% of the familial risk of breast cancer, and the residual genetic variance is likely to be due to variants conferring more moderate risks. To identify further susceptibility alleles, we conducted a two-stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls, followed by a third stage in which 30 single nucleotide polymorphisms (SNPs) were tested for confirmation in 21,860 cases and 22,578 controls from 22 studies. We used 227,876 SNPs that were estimated to correlate with 77% of known common SNPs in Europeans at r 2 . 0.5. SNPs in five novel independent loci exhibited strong and consistent evidence of association with breast cancer (P , 10
27
). Four of these contain plausible causative genes (FGFR2, TNRC9, MAP3K1 and LSP1). At the second stage, 1,792 SNPs were significant at the P , 0.05 level compared with an estimated 1,343 that would be expected by chance, indicating that many additional common susceptibility alleles may be identifiable by this approach.
Breast cancer is about twice as common in the first-degree relatives of women with the disease as in the general population, consistent with variation in genetic susceptibility to the disease 1 . In the 1990s, two major susceptibility genes for breast cancer, BRCA1 and BRCA2, were identified 2, 3 . Inherited mutations in these genes lead to a high risk of breast and other cancers 4 . However, the majority of multiple case breast cancer families do not segregate mutations in these genes. Subsequent genetic linkage studies have failed to identify further major breast cancer genes 5 . These observations have led to the proposal that breast cancer susceptibility is largely 'polygenic': that is, susceptibility is conferred by a large number of loci, each with a small effect on breast cancer risk 6 . This model is consistent with the observed patterns of familial aggregation of breast cancer 7 . However, progress in identifying the relevant loci has been slow. As linkage studies lack power to detect alleles with moderate effects on risk, large case-control association studies are required. Such studies have identified variants in the DNA repair genes CHEK2, ATM, BRIP1 and PALB2 that confer an approximately twofold risk of breast cancer, but these variants are rare in the population [8] [9] [10] [11] [12] [13] [14] . A recent study has shown that a common coding variant in CASP8 is associated with a moderate reduction in breast cancer risk 15 . After accounting for all the known breast cancer loci, more than 75% of the familial risk of the disease remains unexplained 16 . Recent technological advances have provided platforms that allow hundreds of thousands of SNPs to be analysed in association studies, thus providing a basis for identifying moderate risk alleles without prior knowledge of position or function. It has been estimated that there are 7 million common SNPs in the human genome (with minor allele frequency, m.a.f., .5%) 17 . However, because recombination tends to occur at distinct 'hot-spots', neighbouring polymorphisms are often strongly correlated (in 'linkage disequilibrium', LD) with each other. The majority of common genetic variants can therefore be evaluated for association using a few hundred thousand SNPs as tags for all the other variants 18 . We aimed to identify further breast cancer susceptibility loci in a three-stage association study 19 . In the first stage, we used a panel of 266,722 SNPs, selected to tag known common variants across the entire genome 18 . These SNPs were genotyped in 408 breast cancer cases and 400 controls from the UK; data were analysed for 390 cases and 364 controls genotyped for $80% of the SNPs. The cases were selected to have a strong family history of breast cancer, equivalent to at least two affected female first-degree relatives, because such cases are more likely to carry susceptibility alleles 20 . Initally, we analysed 227,876 SNPs (85%) with genotypes on at least 80% of the subjects. We estimate that these SNPs are correlated with 58% of common SNPs in the HapMap CEPH/CEU (Utah residents with ancestry from northern and western Europe) samples at r 2 . 0.8, and 77% at r 2 . 0.5 (mean r 2 5 0.75; see Supplementary  Fig. 1 ) (http://www.hapmap.org/) 21 . As expected, coverage was strongly related to m.a.f.: 70% of SNPs with m.a.f. . 10% were tagged at r 2 . 0.8, compared with 23% of SNPs with m.a.f. 5-10%. The main analyses were restricted to 205,586 SNPs that had a call rate of 90% and whose genotype distributions did not differ from HardyWeinberg equilibrium in controls (at P , 10 25 ). For the second stage we selected 12,711 SNPs, approximately 5% of those typed in stage 1, on the basis of the significance of the difference in genotype frequency between cases and controls. These SNPs were then genotyped in a further 3,990 invasive breast cancer cases and 3,916 controls from the SEARCH study, using a custom-designed oligonucleotide array. In the main analyses, we considered 10,405 SNPs with call rate of .95% that did not deviate from HardyWeinberg equilibrium in controls.
Comparison of the observed and expected distribution of test statistics showed some evidence for an inflation of the test statistics in both stage 1 (inflation factor l 5 1.03, 95% confidence interval (CI) 1.02-1.04) and stage 2 (l 5 1.06, 95% CI 1.04-1.12), based on the 90% least significant SNPs (Fig. 1) . Possible explanations for this inflation include population stratification, cryptic relatedness among subjects, and differential genotype calling between cases and controls. There was evidence for an excess of low call rate SNPs among the most significant SNPs (P , 0.01) in stage 1, but not in stage 2, suggesting that some of this effect is a genotyping artefact (Supplementary Table  1 ). However, the inflation was still present among SNPs with call rate .99% in both cases and controls, possibly reflecting population substructure. We computed 1 degree of freedom (d.f.) association tests for each SNP, combining stages 1 and 2. After adjustment for this inflation by the genomic control method 22 , we observed more associations than would have been expected by chance at P , 0.05 (Table 1) . One SNP (dbSNP rs2981582) was significant at the P , 10 27 level that has been proposed as appropriate for genome-wide studies 23 .
In the third stage, to establish whether any SNPs were definitely associated with risk, we tested 30 of the most significant SNPs in 22 additional case-control studies, comprising 21,860 cases of invasive breast cancer, 988 cases of carcinoma in situ (CIS) and 22,578 controls (Supplementary Table 2 ). Six SNPs showed associations in stage 3 that were significant at P # 10 25 with effects in the same direction as in stages 1 and 2 ( Table 2, Supplementary Table 3 , and Fig. 2 ). All these SNPs reached a combined significance level of P , 10 27 (ranging from 2 3 10 276 to 3 3 10
29
). Of these six SNPs, five were within genes or LD blocks containing genes. SNP rs2981582 lies in intron 2 of FGFR2 (also known as CEK3), which encodes the fibroblast growth factor receptor 2. SNPs rs12443621 and rs8051542 are both located in an LD block containing the 59 end of TNRC9 (also known as TOX3), a gene of uncertain function containing a tri-nucleotide repeat motif, as well as the hypothetical gene, LOC643714. SNP rs889312 lies in an LD block of approximately 280 kb that contains MAP3K1 (also known as MEKK), which encodes the signalling protein mitogen-activated protein kinase kinase kinase 1, in addition to two other genes: MGC33648 and MIER3. SNP rs3817198 lies in intron 10 of LSP1 (also known as WP43), encoding lymphocyte-specific protein 1, an F-actin bundling cytoskeletal protein expressed in haematopoietic and endothelial cells. A further SNP, rs2107425, located just 110 kilobases (kb) from rs3817198, was also identified (overall P 5 0.00002). rs2107425 is within the H19 gene, an imprinted maternally expressed untranslated messenger RNA closely involved in regulation of the insulin growth factor gene, IGF2. In stage 3, however, rs2107425 was only weakly significant after adjustment for rs3817198 by logistic regression (P 5 0.06). This suggests that the association with breast cancer risk may be driven by variants in LSP1 rather than in H19. The sixth SNP reaching a combined P , 10 27 was rs13281615, which lies on 8q. It is correlated with SNPs in a 110 kb LD block that contains no known Under the null hypothesis of no association at any locus, the points would be expected to follow the black line. genes. The basis of this association therefore remains obscure. This SNP is approximately 130 kb proximal to rs1447295, 60 kb proximal to rs6983267 and 230 kb distal to rs16901979, recently shown to be associated with prostate cancer [24] [25] [26] . In addition to the seven SNPs described above, there was evidence of association among the remaining 23 SNPs (global P 5 0.001 in stage 3). In particular, three SNPs showed some evidence of association in stage 3 (P , 0.05, in each case in the same direction as in stages 1 and 2; Table 2 ). SNPs rs981782 and rs30099 both lie in the centromeric region of chromosome 5. rs4666451 lies on 2p, a region for which some evidence of linkage to breast cancer in families has been reported 5 . The 20 other SNPs showed no evidence of association in stage 3 (global P 5 0.11), suggesting that most of these associations from stages 1 and 2 were false positives.
FGFR2
The most significantly associated SNP, rs2981582, lies within a 25 kb LD block almost entirely within intron 2 of FGFR2. We found no evidence of association with SNPs elsewhere in the gene (Fig. 3a) . In an attempt to identify a causal variant, we first identified the 19 common variants (m.a.f. . 0.05) in this block from HapMap CEU data. These were tagged (r 2 . 0.8) by 7 SNPs including rs2981582. The additional tag SNPs were genotyped in the SEARCH study cases and controls. Multiple logistic regression analysis of these variants found no additional evidence for association after adjusting for rs2981582. Haplotype analysis of these 7 SNPs indicated that multiple haplotypes carrying the minor (a) allele of rs2981582 were associated with an increased risk of breast cancer, implying that the association was being driven by rs2981582 itself or a variant strongly correlated with it (Supplementary Table 4) . (Fig. 3b, left panel) . The strongest association was found with rs7895676. On the assumption that there is a single disease-causing allele, we calculated a likelihood for each variant. 21 SNPs (including rs2981582) had a likelihood ratio of ,1/ 100 relative to rs7895676, indicating that none of these are likely to be the causal variant (Supplementary Table 8 ). Six variants were too strongly correlated for their individual effects to be separated using a genetic epidemiological approach. Functional assays will be required to determine which is causally related to breast cancer risk.
Intron 2 of FGFR2 shows a high degree of conservation in mammals, and contains several putative transcription-factor binding sites (http://genomequebec.mcgill.ca/PReMod) 27 , some of which lie in close proximity to the relevant SNPs. We therefore speculate that the association with breast cancer risk is mediated through regulation of FGFR2 expression. Of possible relevance is that only three of these variants (rs10736303, rs2981578 and rs35054928) are within sequences conserved across all placental mammals ( Fig. 3c and Supplementary Table 8 ). Of these, the disease associated allele of rs10736303 generates a putative oestrogen receptor (ER) binding site. rs35054928 lies immediately adjacent to a perfect POU domain protein octamer (Oct) binding site. However, multiple splice variants have been reported in FGFR2, and differential splicing might provide an alternative mechanism for the association. FGFR2 is a receptor tyrosine kinase that is amplified and overexpressed in 5-10% of breast tumours [28] [29] [30] . Somatic missense mutations of FGFR2 that are likely to be implicated in cancer development have also been demonstrated in primary tumours and cell lines of multiple tumour types (http://www.sanger.ac.uk/genetics/CGP/cosmic/) 30, 31 .
TNRC9/LOC643714 locus As two SNPs in the TNRC9/LOC643714 locus, rs12443621 and rs8051542, both showed convincing evidence of association, we further evaluated this region by genotyping, in the SEARCH set, an additional 19 SNPs tagging 101 common variants within the entire TNRC9 and LOC643714 genes, based on the HapMap CEU data. SNPs tagging the coding region of TNRC9 showed no evidence of association. The strongest association was observed with rs3803662, a synonymous coding SNP of LOC643714 that lies 8 kb upstream of TNRC9. This SNP was therefore genotyped in the stage 3 set ( 35 . Red circle indicates rs2981582. SNPs in grey are those used in the initial tagging of known common HapMap SNPs within the block. SNPs in black are correlated with rs2981582 with r 2 . 0.6 in European samples. Six SNPs in red were those consistent with being the causative variant on the basis of the genetic data (not excluded at odds of 100:1 relative to the SNP with the strongest association, rs7895676).
that the causal variant is closely correlated with rs3803662. Four SNPs in the HapMap CEU data (rs17271951, rs1362548, rs3095604 and rs4784227) that span LOC643714 and the 59 regulatory regions of TNRC9 are strongly correlated with rs3803662, and it therefore remains unclear in which gene the causative variant lies. TNRC9 contains a putative HMG (high mobility group) box motif, suggesting that it might act as a transcription factor.
Pattern of risks
We assessed in more detail, in the stage 3 data, the pattern of the risks associated with the five independent SNPs that reached an overall P , 10
27
: rs2981582 (FGFR2), rs3803662 (TNRC9/LOC643714), rs889312 (MAP3K1), rs13281615 (8q) and rs3817198 (LSP1). For each of these five SNPs, the minor allele in Europeans was associated with an increased risk of breast cancer in a dose-dependent manner, with a higher risk of breast cancer in homozygous than in heterozygous carriers. Simple dominant and recessive models could be rejected for each SNP (all P 5 0.02 or less). There was a marked difference in allele frequencies between populations, with the risk-associated alleles of rs8051542, rs889312 and rs13281615 being the major allele in Asian populations. The per allele odds ratio associated with rs2981582 was significantly smaller, though still elevated, in the Asian versus European populations (P 5 0.04 for difference in odds ratio). This difference is consistent with the hypothesis that rs2981582 is not the functional variant at the FGFR2 locus, and was not seen for SNPs exhibiting stronger evidence in the fine-scale mapping. No other evidence for heterogeneity in the per-allele odds ratio among studies was observed (Fig. 2) .
Three of the SNPs (rs2981582, rs3803662 and rs889312) also showed evidence of association with breast CIS (Supplementary Table 9 ). For rs2981582 and rs3803662, the estimated odds ratios were greater for a diagnosis of breast cancer before age 40 years, but the trends by age were not statistically significant (Supplementary Table  10 ). There was evidence of an association with family history of breast cancer for three SNPs: for rs2981582 (P 5 0.02), rs3803662 (P 5 0.03) and rs13281615 (P 5 0.05), the susceptibility allele was commoner in women with a first-degree relative with the disease than in those without (Supplementary Table 11 ). rs2981582 was also associated with bilaterality (P 5 0.02). The associations with family history and bilaterality are to be expected for susceptibility loci, and are similar to previous observations for alleles in CHEK2 and ATM (refs 10, 12, 14) .
Discussion
This study has identified five novel breast cancer susceptibility loci, and demonstrated conclusively that some of the variation in breast cancer risk is due to common alleles. None of the loci we identified had been previously reported in association studies. Most previously identified breast cancer susceptibility genes are involved in DNA repair, and many association studies in breast cancer have concentrated on genes in DNA repair and sex hormone synthesis and metabolism pathways. None of the associations reported here appear to relate to genes in these pathways. It is notable that three of the five loci contain genes related to control of cell growth or to cell signalling, but only one (FGFR2) had a clear prior relevance to breast cancer. These results should, therefore, open up new avenues for basic research.
Our results emphasize the critical importance of study size in genetic association studies. It is notable that none of the confirmed associations reached genome-wide significance after stage 1 and only one reached this level after stage 2. As most common cancers have similar familial relative risks to breast cancer, it is likely that similarly large studies will be required to identify common alleles for other cancers. The fine-scale mapping of the FGFR2 locus demonstrates that, even with a clear association, identification of the causative variant can be extremely problematic. However, the use of studies from multiple populations with different patterns of LD can substantially reduce the number of variants that need to be subjected to functional analysis.
As these susceptibility alleles are very common, a high proportion of the general population are carriers of at-risk genotypes. For example, approximately 14% of the UK population and 19% of UK breast cancer cases are homozygous for the rare allele at rs2981582. On the other hand, the increased risks associated with these alleles are relatively small-on the basis of UK population rates, the estimated breast cancer risk by age 70 years for rare homozygotes at rs2981582 is 10.5%, compared to 6.7% in heterozygotes and 5.5% in common homozygotes. At this stage, it is unlikely that these SNPs will be appropriate for predictive genetic testing, either alone or in combination with each other. However, as further susceptibility alleles are identified, a combination of such alleles together with other breast cancer risk factors may become sufficiently predictive to be important clinically.
On the basis of the relative risk estimates from stage 3, and assuming that the five most significant loci interact multiplicatively on disease risk, these loci explain an estimated 3.6% of the excess familial risk of breast cancer. On the basis of our staged design and the estimated distribution of linkage disequilibrium between the typed SNPs and those in HapMap, we estimate that the power to identify the five most significant associations at P , 10 27 (rs2981582, rs3803662, rs889312, rs13281615 and rs3817198) was 93%, 71%, 25%, 3% and 1% respectively. These estimates are uncertain, notably because the true coverage of HapMap SNPs is unknown. Nevertheless, these calculations indicate that the power to detect the two strongest associations was high, and suggest that there are likely to be few other common variants with a similar effect on variation in breast cancer risk to rs2981582. In contrast, the low power to detect rs13281615 and rs3817198 suggests that these variants may represent a much larger class of loci, each explaining of the order of 0.1% of the familial risk of breast cancer. An example of such a locus is provided by CASP8 D302H, which showed strong evidence of association in a previous large study 15 . This SNP was tested in stage 1, but the association was missed because it did not reach the threshold for testing in stage 2. The excess of associations after stage 2 is also consistent with the existence of many such loci. In addition, because the coverage for SNPs with m.a.f. , 10% was low, many low frequency alleles may have been missed. The detection of further susceptibility loci will require genome-wide studies with more complete coverage and using larger numbers of cases and controls, together with the combination of results across multiple studies. The present study demonstrates that common susceptibility loci can be reliably identified, and that they may together explain an appreciable fraction of the genetic variance in breast cancer risk.
METHODS SUMMARY
Cases for stage 1 were identified through clinical genetics centres in the UK and a national study of bilateral breast cancer. Cases in stage 2 were drawn from a population-based study of breast cancer (SEARCH) 32 . Controls for stages 2 and 3 were drawn from EPIC-Norfolk, a population-based study of diet and cancer 33 . Cases and controls for stage 3 were identified through case-control studies in Europe, North America, South-East Asia and Australia participating in the Breast Cancer Association Consortium (Supplementary Table 2) 34 . Genotyping for stages 1 and 2 was conducted using high-density oligonucleotide microarrays. For the main analyses, we excluded samples called on #80% of SNPs in either stage. We also excluded SNPs that achieved a call rate of #90% in stage 1 and #95% in stage 2, and SNPs whose frequency deviated from HardyWeinberg equilibrium in controls at P , 0.00001. Genotyping for stage 3, and for the fine-scale mapping of the FGFR2 locus, was conducted using either a 59 nuclease assay (Taqman, Applied Biosystems) or MALDI-TOF mass spectrometry using the Sequenom iPLEX system. For each centre, we excluded any sample called on #80% of SNPs, and any SNP with a call rate of #95% or a deviation from Hardy-Weinberg equilibrium in controls at P , 0.00001. Tests of association were 1 d.f. Cochran-Armitage tests, stratified for stage, centre and ethnic group (European or Asian). Odds ratios for each SNP were estimated using stratified logistic regression, using the stage 3 data only.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
METHODS
Subjects. Cases in stage 1 were identified through clinical genetics centres in Cambridge (n 5 91), Manchester (96) and Southampton (136), and a national study of bilateral breast cancer (85). Cases were women diagnosed with invasive breast cancer under the age of 60 years who had a family history score of at least 2, where the score was computed as the total number of first-degree relatives plus half the number of second-degree relatives affected with breast cancer. The score for women with bilateral breast cancer was increased by 1, so that women were eligible if they were diagnosed with bilateral breast cancer and had one affected first-degree relative. Cases known to carry a BRCA1 or BRCA2 mutation were excluded. Controls were selected from the EPIC-Norfolk study, a populationbased cohort study of diet and cancer based in Norfolk, East Anglia, UK 33 . Controls were chosen to be women aged over 50 years and free of cancer at the time of entry. Genotyping was attempted on 408 cases, plus 32 duplicate case samples, and 400 controls. For the analysis in Table 1 , 54 samples with genotype call rates ,80% were excluded, so the final analyses were based on 390 cases and 364 controls. The minimum genotype call rate for the remaining samples was 89%. The overall genotype discordance rate between duplicate samples in stage 1 was 0.01%.
For stage 2, invasive breast cancer cases were drawn from SEARCH, a population-based study of cancer in East Anglia 32 . Controls were women selected from the EPIC-Norfolk study, as previously described 33 . Eighty-eight subjects who were also genotyped in stage 1, and 35 controls who subsequently developed breast cancer and were also in the case series, were excluded from the analysis, leaving 3,990 breast cancer cases and 3,916 controls, plus five duplicates. The overall rate of discordance of genotypes between duplicate samples in stage 2 was 0.008%.
Twenty-one additional studies were included in stage 3 (see Supplementary  Table 2 ). These studies participated through the Breast Cancer Association Consortium, an ongoing collaboration among investigators conducting casecontrol association studies in breast cancer 15, 33 . All studies provided information on disease status (invasive breast cancer, carcinoma in situ or control), age at diagnosis/observation, ethnic group, first-degree family history of breast cancer and bilaterality of breast cancer. One further study (Breast Cancer Study of Taiwan) was included in the fine-scale mapping of the FGFR2 locus. Genotyping. For stage 1, genotyping was performed on 200 ng DNA that was first subjected to whole genome amplification using Multiple Displacement Amplification (MDA) 36 . Samples were then genotyped for a set of 266,732 SNPs using high-density oligonucleotide, photolithographic microarrays at Perlegen Sciences. For stage 2, genotyping was performed using 2.5 mg genomic DNA. These samples were genotyped for a set of 13,023 SNPs selected on the basis of the stage 1 results, using a custom designed oligonucleotide array. For both stages, each SNP was interrogated by 24 25-mer oligonucleotide probes synthesized by photolithography on a glass substrate. The 24 features comprise 4 sets of 6 features interrogating the neighbourhoods of SNP reference and alternative alleles on forward and reference strands. Each allele and strand is represented by five offsets: 22, 21, 0, 1 and 2 indicating the position of the SNP within the 25-mer, with zero being at the thirteenth base. At offset 0 a quartet was tiled, which included the perfect match to reference and alternative SNP alleles, and the two remaining nucleotides as mismatch probes. When possible, the mismatch features were selected as a purine nucleotide substitution for a purine perfect match nucleotide and a pyrimidine nucleotide substitution for a pyrimidine perfect match nucleotide. Thus, each strand and allele tiling consisted of 6 features comprising five perfect match probes and one mismatch.
Individual genotypes were determined by clustering all SNP scans in the twodimensional space defined by reference and alternative trimmed mean intensities, corrected for background. Allele frequencies were approximated using the intensities collected from the high-density oligonucleotide arrays. An SNP's allele frequency, p, was estimated as the ratio of the relative amount of the DNA with reference allele to the total amount of DNA. Thep p value was computed from the trimmed mean intensities of perfect match features, after subtracting a measure of background computed from trimmed means of intensities of mismatch features. The trimmed mean disregarded the highest and the lowest intensity from the five perfect match intensities before computing the arithmetic mean. For the mismatch features, the trimmed mean is the individual intensity of the specified mismatch feature.
The genotype clustering procedure was an iterative algorithm developed as a combination of K-means and constrained multiple linear regressions. The K-means at each step re-evaluated the cluster membership representing distinct diploid genotypes. The multiple linear regressions minimized the variance inp p within each cluster while optimizing the regression lines' common intersect. The common intersect defined a measure of common background that was used to adjust the allele frequencies for the next step of K-means. The K-means and multiple linear regression steps were iterated until the cluster membership and background estimates converged. The best number of clusters was selected by maximizing the total likelihood over the possible cluster counts of 1, 2 and 3 (representing the combinations of the three possible diploid genotypes). The total likelihood was composed of data likelihood and model likelihood. The data likelihood was determined using a normal mixture model for the distribution of p p around the cluster means. The model likelihood was calculated using a prior distribution of expected cluster positions, resulting in optimalp p positions of 0.8 for the homozygous reference cluster, 0.5 for the heterozygous cluster and 0.2 for the homozygous alternative cluster.
A genotyping quality metric was compiled for each genotype from 15 input metrics that described the quality of the SNP and the genotype. The genotyping quality metric correlated with a probability of having a discordant call between the Perlegen platform and outside genotyping platforms (that is, non-Perlegen HapMap project genotypes). A system of 10 bootstrap aggregated regression trees was trained using an independent data set of concordance data between Perlegen genotypes and HapMap project genotypes. The trained predictor was then used to predict the genotyping quality for each of the genotypes in this data set. Genotypes with quality scores of less than 7 were discarded. Data were analysed for 227,876 SNPs in stage 1 and 12,026 (of 13,023 selected) in stage 2, for which the call rate was .80%.
The 12,711 SNPs for stage 2 were primarily selected on the basis of a 1 d.f. Cochran-Armitage trend test (11, 809 , all with P , 0.052). We also included 826 SNPs with P , 0.01 testing for the difference in frequency of either homozygote between cases and controls (that is, assuming either a dominant or recessive model) and 76 SNPs that achieved P , 0.01 on a Cochran-Armitage test, weighting individuals by their family history score as above.
For the main analyses, we discarded SNPs with a call rate ,90% in stage 1 and 95% in stage 2, and SNPs with a deviation from Hardy-Weinberg equilibrium significant at P , 0.00001 in either stage, leaving 205,586 SNPs in stage 1 and 10,621 SNPs in stage 2.
The 30 SNPs included in the stage 3 analyses were initially selected on the basis of a combined analysis of stage 1 and stage 2. We included all SNPs achieving a combined P , 0.00002 (based on either the Cochran-Armitage or 2 d.f. test, see below). Following re-evaluation of the stage 2 genotyping by 59 nuclease assay (Taqman, Applied Biosystems) using the ABI PRISM 7900HT (Applied Biosystems), and exclusion of some samples, 16 of these SNPs were significant at P , 0.00002 and 24 at P , 0.0002 (Supplementary Table 3) . One additional SNP, rs3803662, was added as a result of fine-scale mapping of the TNRC9/ LOC643714 locus.
The 31 stage 3 SNPs were genotyped in 22 studies (including cases and controls from SEARCH not used in stage 2, together with 21 other studies). For 18 of the studies, genotyping was performed by 59 nuclease assay (Taqman) using the ABI PRISM 7900HT or 7500 Sequence Detection Systems according to manufacturer's instructions. Primers and probes were supplied directly by Applied Biosystems (http://www.appliedbiosystems.com/) as Assays-by-Design. All assays were carried out in 384-well or 96-well format, with each plate including negative controls (with no DNA). Duplicate genotypes were provided for at least 2% of samples in each study. For three studies, SNPs were genotyped using matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) for the determination of allele-specific primer extension products using Sequenom's MassARRAY system and iPLEX technology. The design of oligonucleotides was carried out according to the guidelines of Sequenom and performed using MassARRAY Assay Design software (version 1.0). Multiplex PCR amplification of amplicons containing SNPs of interest was performed using Qiagen HotStart Taq Polymerase on a Perkin Elmer GeneAmp 2400 thermal cycler (MJ Research) with 5 ng genomic DNA. Primer extension reactions were carried out according to manufacturer's instructions for iPLEX chemistry. Assay data were analysed using Sequenom TYPER software (version 3.0). One study used both the Taqman and MALDI-TOF MS approaches. The SNPs genotyped in stage 3 were also regenotyped in the stage 2 samples using Taqman; these genotype calls were used in the overall analyses (Table 2,  Supplementary Table 3 , and Fig. 2) .
We eliminated any sample that could not be scored on 20% of the SNPs attempted. We also removed data for any centre/SNP combination for which the call rate was less than 90%. In any instances where the call rate was 90-95%, the clustering of genotype calls was re-evaluated by an independent observer to determine whether the clustering was sufficiently clear for inclusion. We also eliminated all the data for a given SNP/centre where the reproducibility in duplicate samples was ,97%, or where there was marked deviation from Hardy-Weinberg equilibrium in the controls (P , 0.00001). Fine-scale mapping of FGFR2. Initial tagging of the associated region was done by identifying all SNPs with an m.a.f. . 5% in the HapMap CEPH/CEU set (Utah residents with ancestry from northern and western Europe). We then selected 7 SNPs (in addition to rs2981582) that tagged these variants with a doi:10.1038/nature05887
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Publishing Group pairwise r 2 . 0.8, using the program Tagger (http://www.broad.mit.edu/mpg/ tagger/) 37 . To identify additional common variants within the 32.5 kb region of linkage around the associated SNP, we resequenced 45 lymphocyte DNA samples from a subset of European subjects also genotyped by HapMap and other publicly available data sets. Seventy overlapping PCR amplicons were designed from positions 123317613 to 123348192 of chromosome 10 (average amplicon size 650 bp, 160 bp overlap). M13-tagged PCR products were bidirectionally sequenced using Big Dye 3.0 (Applied Biosystems) and processed using automated trace analysis through the Cancer Genome Workbench (cgwb.nci.nih.-gov). Eighty-six per cent of the nucleotides across the region could be scored for polymorphisms in at least 80% of subjects. This set gave a .97% probability of detecting a variant with an m.a.f. . 5%. One hundred and seventeen variants were identified, including 27 present in dbSNP but without individual genotype information in European subjects, and an additional 46 not in dbSNP. Individual genotype information was then compared and merged with publicly available genotypes from Caucasian subjects (HapMap release 21 for 60 CEU parents, 22 European subjects from the Environmental Genome Project (EGP) resequencing effort (http://egp.gs.washington.edu/data/fgfr2/), and 24 European subjects from Perlegen (retrieved through http://gvs.gs.washington.edu/ GVS)). There were 2 discrepancies among 389 genotype calls among subjects in common between our resequencing effort and EGP or Perlegen data, and 10 out of 926 compared to HapMap genotypes.
On the basis of these data, we identified 28 SNPs correlated with rs2981582 with r 2 . 0.6. We then attempted to genotype these 28 SNPs, plus rs2981582, in a subset of 80 controls from SEARCH and 84 controls from the Seoul Breast Cancer Study. Twenty-two of the variants were genotyped using Taqman. Four further variants (rs34032268, rs2912778, rs2912781 and rs7895676), which were not amenable to Taqman, were genotyped by Pyrosequencing (Biotage; http://www.biotagebio.com/). Assays were designed using Pyrosequencing Assay Design Software 1.0. The remaining 2 SNPs (rs35393331 and rs33971856) could not be genotyped using either technology and were excluded from further analyses. We cannot therefore comment on their likelihood of being the causal variant. Using these data, we selected tagging sets of 11 SNPs for UK subjects and 14 SNPs for Korean subjects (including rs2981582), such that each of the remaining variants was correlated with a tagging SNP with r 2 . 0.95 in the UK study or r 2 . 0.86 in the Korean study. After genotyping the 11 tag SNPs in SEARCH, two of these SNPs (rs4752569 and rs35012336) showed strong evidence against being the causative variant and were not considered further. The remaining 12 tag SNPs from the Korean subset were then genotyped in the samples from the IARC-Thai Breast Cancer Study, the Breast Cancer Study in Taiwan and the Multi-Ethnic Cohort (MEC), by Taqman. Statistical methods. The primary test used for each SNP was a CochranArmitage 1 d.f. score test for association between disease status and allele dose. In the combined analysis, we performed a stratified Cochran-Armitage test. Stage 1 was given a weight of 4 in this analysis (corresponding to a weight of 2 in the score statistic), to allow for the expected greater effect size given the inclusion of cases with a family history. In the stage 3 analyses, each study was treated as a separate stratum, except for the MEC, in which the European American and Japanese American subgroups were treated as separate strata. For all studies except the MEC, individuals from a minor ethnic group for that study were excluded. Per-allele and genotype-specific odds ratios, and confidence intervals, were estimated using logistic regression, adjusting for the same strata. The summary odds ratios in Fig. 2 are based on the data from the stage 3 studies only, to avoid the bias inherent in estimates from the stage 1 and 2 data for SNPs exhibiting an association (the so called 'winner's curse'). The effects of genotype on family history of breast cancer (first degree yes/no) and bilaterality were examined by treating these variables as outcomes in a stratified CochranArmitage test.
To assess the global significance of the SNPs in stage 3, we computed the sum of the x 2 trend statistics (excluding the 6 SNPs reaching genome-wide significance, plus rs2107425 as it was in LD with rs3817198) over those SNPs (17 of 23) for which the estimated odds ratios in stage 3 were in the same direction as the combined stage 1/stage 2 38 . Under the null hypothesis of no association, the asymptotic distribution of this statistic is x 2 with n degrees of freedom, where n has a binomial distribution with parameters 23 and 1/2. The significance of this statistic was then assessed by computing a weighted sum of the tails of the relevant x 2 distributions. For the fine-scale mapping of the FGFR2 locus, we first derived haplotype frequencies using the haplo.stats package in S-plus 39 , separately for the European and Asian populations, using data from the case-control studies on whom the tag SNPs were typed plus the 164 control individuals on whom all SNPs were typed. These were used to impute genotype probabilities for each identified SNP in each individual. We then used an EM algorithm to fit a logistic regression model assuming that each SNP in turn was the causal variant, allowing for uncertainty in the genotypes of untyped SNPs, and hence to determine the likelihood that each SNP was the causal variant.
Coverage of the stage 1 tagging set was estimated using HapMap phase II as a reference. We based estimates on 2,116,183 SNPs with an m.a.f. of .5% in the CEU population. Of the SNPs successfully genotyped in stage 1, 187,663 were also on HapMap. For those SNPs not on HapMap, we identified 'surrogate' SNPs that were in perfect LD based on genotyping of 24 Caucasians by Perlegen Sciences (269,203 SNPs) 18 . To estimate coverage, we determined the best pairwise r 2 for each HapMap SNP and each tag SNP or a surrogate SNP, using the HapMap CEU data. This coverage was summarized in terms of the distribution of r 2 by allele frequency in 10 categories.
To estimate the power to detect each of the associations found, we computed the non-centrality parameter for the test statistic at each stage, based on the perallele relative risk, allele frequency and r
2
. This was used to estimate the power for a given r 2 , based on a simulated trivariate normal distribution for the score statistics after each stage to allow for the correlations in the test statistics. We assumed a cut-off of P , 0.05 for stage 1, P , 0.00002 for stage 2 and P , 10 27 for stage 3 (the first is slightly conservative, as more SNPs than this were actually taken forward). The overall power was obtained by averaging the power estimates for each r 2 over the distribution of r 2 obtained from the HapMap data, applicable to a SNP of that frequency.
The expected number of significant associations after stage 2 ( Table 1 ) was calculated using a bivariate normal distribution for the joint distribution of the (weighted) Cochran-Armitage score statistics after stage 1 and after both stages, using a correlation of 0.525 between the two statistics (reflecting the weighted sizes of the two studies). These calculations were based on the 205,586 SNPs reaching the required quality control in stage 1. Of these, 11,313 reached a P , 0.05, of which 7,405 (65.5%) were successfully genotyped to the required quality control in stage 2. Thus the expected number reaching a given significance level with good quality control was calculated from the total number expected to reach this level 3 65.5%. We adjusted the variances of the test statistics, separately for stages 1 and 2, using the genomic control method 22 . The adjustment factor, l, was estimated from the median of the smallest 90% of the test statistics for SNPs typed in that stage, divided by the predicted median for the smallest 90% of a sample of x We have genotyped 14,436 nonsynonymous SNPs (nsSNPs) and 897 major histocompatibility complex (MHC) tag SNPs from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease (AITD), multiple sclerosis (MS) and breast cancer (BC). Comparing these data against a common control dataset derived from 1,500 randomly selected healthy British individuals, we report initial association and independent replication in a North American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmation of the previously reported association of AITD with TSHR and FCRL3. These findings, enabled in part by increased statistical power resulting from the expansion of the control reference group to include individuals from the other disease groups, highlight notable new possibilities for autoimmune regulation and suggest that IL23R may be a common susceptibility factor for the major 'seronegative' diseases.
Genome-wide association scans are currently revealing a number of new genetic variants for common diseases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . We have recently completed the largest and most comprehensive scan conducted to date, involving genome-wide association studies of 2,000 individuals from each of seven common disease cohorts and 3,000 common control individuals using a dense panel of 4500,000 markers 12 . In parallel with this scan, we conducted a study of 5,500 independent individuals with a genome-wide set of nonsynonymous coding variants, an approach that has recently yielded new findings about type 1 diabetes and Crohn's disease and that has been proposed as an efficient complementary approach to whole-genome scans [13] [14] [15] . Here we report several new replicated associations in our scan of nsSNPs in 1,500 shared controls and 1,000 individuals from each of four different diseases: ankylosing spondylitis, AITD (of which all had Graves' disease), breast cancer and multiple sclerosis.
RESULTS
Initial genotyping was carried out with a custom-made Infinium array (Illumina) and involved 14,436 nsSNPs (assays were synthesized for 16,078 nsSNPs). At the inception of the study, this comprised the complete set of experimentally validated nsSNPs with minor allele frequency (MAF) 4 1% in western European samples. In addition, because three of the diseases were of autoimmune etiology, we also typed a dense set of 897 SNPs throughout the MHC that, together with 348 nsSNPs in this region, provided comprehensive tag SNP coverage (r 2 Z 0.8 with all SNPs in ref. 16 ). Finally, 103 SNPs were typed in pigmentation genes specifically designed to differentiate between population groups. Similar to those from previous studies, our data revealed that detailed assessment of initial data is critical to the process of association inference, as biases in genotype calling lead to inflation of false-positive rates 12, 17 . This inflation is exaggerated in nsSNP data, because nsSNPs tend to have lower allele frequencies than otherwise anonymous genomic SNPs, and genotype calling is often most difficult for rare alleles. If only cursory filtering had been applied in the present case, numerous false-positives would have emerged ( Supplementary Figs. 1-4 online). Table 1 shows the total number of SNPs and individuals remaining after genotype and sample quality control procedures (see Methods).
Association with the MHC
The strongest associations observed in the study were between SNPs in the MHC region and the three autoimmune diseases studiedankylosing spondylitis, AITD and MS-with P values of o10 -20 for each disease (Fig. 1) . No association of the MHC was seen with breast cancer (P 4 10 -4 across the region). For each of the autoimmune diseases, the maximum signal was centered around the known HLAassociated genes (for example, those encoding HLA-B in ankylosing spondylitis, HLA-DRB1 in MS and the MHC class I and class II molecules in AITD), but in all cases, it extended far beyond the specific associated haplotype(s). For example, in ankylosing spondylitis, association was observed at P o 10 -20 across B1.5 Mb. Given the well-known strong effect of HLA-B27 variant on the probability of developing ankylosing spondylitis (odds ratio 100-200 in most populations), the extent of this association signal reflects that with such large effects, even very distant SNPs in modest linkage disequilibrium (LD) will show indirect evidence for association. Strong signals like these may also cloud the evidence for additional HLA loci 18 . Disentangling similar patterns of association within the MHC has proven extremely challenging in the past and will be addressed in future studies of these data. Here we focus specifically on the nsSNP results. © 2007 Nature Publishing Group http://www.nature.com/naturegenetics Association with nsSNPs A major advantage of the Wellcome Trust Case Control Consortium (WTCCC) design is the availability of multiple disease cohorts that are similar in terms of ancestry and that have been typed on the same genetic markers 12, 17 . Assuming that each disease has at least some unique genetic loci, we hypothesized that combining the other three case groups with the controls for the 1958 birth cohort (58C) 19 would increase power to detect association. For each disease, we therefore conducted two primary analyses: first, we tested nsSNP associations for each disease against the controls in the 58C; and second, we tested the same associations for each disease against an expanded reference group comprising the combined cases from the other three disease groups plus individuals from the 58C. A similar set of analyses was conducted for each of the autoimmune disorders against a reference group comprising 58C controls and individuals with breast cancer, but the results were very similar to those for the fully expanded groups, so here we describe the larger sample (Supplementary Table 1 online) . In addition, because it is possible that different autoimmune diseases share similar genetic etiologies, we also compared a combined ankylosing spondylitis, AITD and MS group (immune cases) against the combined set of individuals with breast cancer and 58C controls. All of our analyses are reported without regard to specific treatment of population structure, as the degree of structure in our final genotype data is not severe (Genomic Control 20 l ¼ 1.07-1.13 in the 58C-only datasets; l ¼ 1.03-1.06 in the expanded reference group comparisons; Table 2 ), consistent with our recent findings from 17,000 UK individuals involving the same controls 12 .
nsSNP association results (excluding the MHC region) for each of the four disease groups against the 58C controls are shown in Figure 2 and Table 3 . Two SNPs on chromosome 5 reached a high level of statistical significance for ankylosing spondylitis (rs27044: P ¼ 1.0 Â 10 -6 ; rs30187: P ¼ 3.0 Â 10 -6 ). This level of significance exceeds the 10 -5 -10 -6 thresholds advocated for gene-based scans 21 -4 , with an increasing number of possible associations at more modest significance levels. Several of the more strongly associated SNPs, and others in the same genes, have been previously associated with these particular diseases, and for yet others there exists functional evidence of involvement in these particular conditions. Among these are SNPs in FCRL3 and FCRL5 in the case of AITD, IL23R in the case of ankylosing spondylitis, MEL18 in the case of breast cancer and IL7R for MS. The complete list of single-marker association results is provided in Supplementary Table 1 .
The results of analyses involving the expanded reference group are presented in Supplementary Figure 5 Table 1 . Many of the SNPs that showed moderate to strong evidence for association in the initial analysis had substantially greater significance when the larger reference group was used. Notably, these included the SNPs rs27044 (P ¼ 4.0 Â 10 -8 ) and rs30187 (P ¼ 2.1 Â 10 -7 ) in ARTS1, as well as several other variants in this gene. A second SNP, rs7302230 in the gene encoding calsyntenin-3 on chromosome 12, showed substantially stronger evidence for association in the expanded reference group analysis (P ¼ 5.3 Â 10 -7 ) relative to the 58C-only results (P ¼ 1.1 Â 10 -4 ). Results of the expanded group also showed elevated results for several SNPs that did not appear exceptional in the original (non-combined) analyses, including SNPs in several candidate genes such as those encoding sialoadhesin 22 and complement receptor 1 for ankylosing spondylitis, PIK3R2 for MS, and C8B, IL17R and TYK2 in the combined autoimmune disease analysis. SNP rs3783941 in the gene TSHR, encoding the thyroid-stimulating hormone receptor, emerged as among the most significant in the expanded reference group analyses of AITD (P ¼ 2.1 Â 10 -5 ). Several polymorphisms in TSHR have previously been associated with Graves' disease 23, 24 . This known association did not reach even the modest significance level of 10 -3 in the original analyses, but the addition of 3,000 further reference samples delineated it from the background noise and further supports the original independent report. ARTS1 association confirmed in an independent cohort To validate the most exceptional findings from the initial study, we genotyped the ARTS1, CLSTN3 and LNPEP SNPs in 471 independent ankylosing spondylitis cases ( Table 4 ) and 625 new controls (all self identified North American Caucasian). The data strongly suggest that the ARTS1 association is genuine. All ARTS1 nsSNPs revealed independent replication in the same direction of effect, with replication significance levels ranging from 4.7 Â 10 -4 to 5.1 Â 10 -5 . When combined with the original samples, the results showed strong evidence for association with ankylosing spondylitis (P ¼ 1.2 Â 10 -8 to 3.4 Â 10 -10 ). The population attributable risk 25 contributed by the most strongly associated marker in the North American dataset (rs2287987) was 26%.
Association was also confirmed with marker rs2303138 in the LNPEP gene, which lies 127 kb 3¢ of ARTS1. This marker was in strong LD with ARTS1 markers (D¢ ¼ 1, rs27044-rs2303138). We tested the interdependence of the ARTS1 and LNPEP associations using conditional logistic regression. The remaining association at LNPEP was weak after controlling for ARTS1 (P ¼ 0.01), whereas the association at ARTS1 remained strong after controlling for LNPEP (P ¼ 2.7 Â 10 -6 ), suggesting that the LNPEP association may only be secondary to LD, with a true association at ARTS1.
No association was seen with CLSTN3 in the confirmation set. The US controls showed the same allele frequency as the UK controls (5%), but the allele frequency in the US cases was less than that of the UK cases (6% versus 8%), suggesting no association in the US samples and substantially reducing the significance of the combined data. Calystenin-3 is a postsynaptic neuronal membrane protein and is an unlikely candidate for involvement in inflammatory arthritis. The failure to replicate this association suggests that our replication sample size was insufficient to detect the modest effect or that it was a false positive in the initial scan.
IL23R variants confer risk of ankylosing spondylitis
The IL23R variant rs11209026, although not notable in the initial nsSNP scan (P ¼ 1.7 Â 10 -3 ), was of particular interest, as it has recently been associated with both Crohn's disease 26, 27 and psoriasis 28 , conditions that commonly co-occur with ankylosing spondylitis. To better define this association, seven additional SNPs in IL23R were genotyped in the same 1,000 British ankylosing spondylitis cases and 1,500 58C controls as well as the North American Caucasian replication samples ( Table 4 ). In the WTCCC dataset, we observed strong association in seven of eight genotyped SNPs (P r 0.008, including the original nsSNP rs11209026), with the strongest association at rs11209032 (P ¼ 2.0 Â 10 -6 ). In the replication dataset, we noted association with all genotyped SNPs (P r 0.04), with peak association with marker rs10489629 (P ¼ 4.2 Â 10 -5 ). In the combined dataset, © 2007 Nature Publishing Group http://www.nature.com/naturegenetics the strongest association observed was with SNP rs11209032 (odds ratio 1.3, 95% confidence interval 1.2-1.4, P ¼ 7.5 Â 10 -9 ). The attributable risk for this marker in the replication cohort is 9%. Conditional logistic regression analyses did not indicate a single primary disease-associated marker; residual association remained after we controlled for association at the remaining SNPs. Considering only individuals with ankylosing spondylitis who self-reported as not having inflammatory bowel disease (n ¼ 1,066) the association remained strong and was still strongest at rs11209032 (P ¼ 6.9 Â 10 -7 ), indicating that there is a primary association with ankylosing spondylitis and that the observed association was not due to coexistent clinical inflammatory bowel disease. In contrast to the pleiotropic effects of IL23R, the ARTS1 association evidence seems confined to ankylosing spondylitis. We genotyped © 2007 Nature Publishing Group http://www.nature.com/naturegenetics 
FCRL3 confirmed in AITD pathogenesis
In addition to the ankylosing spondylitis replications, we attempted to confirm and extend the FCRL3 association in AITD. The SNP rs7522061 in the FCRL3 gene was recently reported to be associated with AITD 29 and two other autoimmune diseases, rheumatoid arthritis and systemic lupus erythematosus 30 . Our initial association evidence (P ¼ 2.1 Â 10 -4 ) likely reflects the signal of the originally detected polymorphism, because the level of LD is high across this gene. In fact, the entire 1q21-q23 region (which includes another gene, FCRL5, flagged in our scan) has also been implicated in several autoimmune diseases, including psoriasis and multiple sclerosis 31, 32 .
On the basis of the original findings on 1q21-q23, the original cohort was increased from 1,000 to 2,500 Graves disease cases, and we used 2,500 controls from the 58C control set. We selected eight SNPs that tagged the FCRL3 and FCRL5 gene regions and typed them in all 5,000 samples using an alternative genotyping platform. SNP rs3761959, which tags rs7522061 and rs7528684 (previously associated with rheumatoid arthritis and Graves' disease), was associated with Graves' disease in this extended cohort (Table 5) , confirming the original result. In total, three of the seven FCRL3 SNPs showed some evidence for association (P o 0.05), with SNP rs11264798 showing the strongest association of the tag SNPs (P ¼ 4.0 Â 10 -3 ). SNP rs6667109 in FCRL5, which tagged SNPs rs6427384, rs2012199 and rs6679793, all found to be weakly associated in the original study, showed little evidence of association in this extended cohort.
DISCUSSION
Our scan of nsSNPs has identified and validated two new genes (ARTS1 and IL23R) associated with ankylosing spondylitis, confirmed and extended markers in the TSHR and FCRL3 genes that have previously been associated with AITD, and provided a dense set of association data for AITD, ankylosing spondylitis and MS across the MHC region. The challenge now is to design functional studies that © 2007 Nature Publishing Group http://www.nature.com/naturegenetics will reveal how variation in these genes translates into physiological processes that influence disease risk. From a functional perspective, ARTS1 and IL23R represent excellent biological candidates for association with ankylosing spondylitis. The protein ARTS1 has two known functions, either of which may explain the association. First, within the endoplasmic reticulum, ARTS1 is involved in trimming peptides to the optimal length for MHC class I presentation 33, 34 . Ankylosing spondylitis is primarily an HLA class Imediated autoimmune disease 35 , with 490% of cases carrying the HLA-B27 allele. How HLA-B27 increases risk of developing ankylosing spondylitis is unknown, but if the association of ARTS1 with the disease relates to effects of ARTS1 on peptide presentation, this relationship would inform research into the mechanism underlying the association of HLA-B27 with ankylosing spondylitis. Second, ARTS1 cleaves cell surface receptors for the pro-inflammatory cytokines IL-1 (IL-1R2) 36 , IL-6 (IL-6Ra) 37 and TNF (TNFR1) 38 , thereby downregulating their signaling. Genetic variants that alter the functioning of ARTS1 could therefore have pro-inflammatory effects through this mechanism.
In addition to their association with ankylosing spondylitis, polymorphisms in IL23R have been recently documented in Crohn's disease 26, 27 and psoriasis 28 , suggesting that this gene is a common susceptibility factor for the major 'seronegative' diseases, at least partially explaining their co-occurrence. IL-23R is a key factor in the regulation of a newly defined effector T-cell subset, T H 17 cells. T H 17 cells were originally identified as a distinct subset of T-cells expressing high levels of the pro-inflammatory cytokine IL-17 in response to stimulation, in addition to IL-1, IL-6, TNFa, IL-22 and IL-25 (IL-17E). IL-23 has been shown to be important in the mouse models of experimental autoimmune encephalomyelitis 39 , collagen-induced arthritis 40 and inflammatory bowel disease 41 , but it has not been studied in ankylosing spondylitis, either in human or other animal models of the disease. These studies show that blocking IL-23 reduces inflammation in these models, suggesting that the IL23R variants associated with disease are pro-inflammatory. Successful treatment of Crohn's disease has been reported with anti-IL-12p40 antibodies, which block both IL-12 and IL-23, as these cytokines share the IL-12p40 chain 42 . No functional studies of IL23R variants have been reported to date, and it is unclear to what extent findings in studies targeting IL-23 can be generalized to mechanisms by which IL23R variation affects disease susceptibility. Our genetic findings provide notable insight into the etiopathogenesis of ankylosing spondylitis and suggest that treatments targeting IL-23 may prove effective for this condition, but clearly much more needs to be understood about the mechanism underlying the observed association.
Despite the successful identification of the ARTS1 and IL23R genes, it is likely either that additional real associations are present in our data but were overlooked because of their modest effect sizes, or that our focus on non-synonymous coding changes led us to miss real loci. The issue of limited statistical power is emphasized in studies of nonsynonymous coding changes, which have a greater number of rare variants than other genetic variants and thus will require even larger sample sizes unless the effect sizes are larger. Other analytical approaches, such as assessing evidence for association between clusters of rare variants rather than individual loci, may prove highly informative in this regard 43 , but most of the nsSNPs available in this study exist either by themselves in each gene or with one or two others, which precludes these assessments ( Supplementary Fig. 6 online) . In our analyses, ARTS1 was the only locus showing exceptional statistical significance in the scan of 1,000 cases and 1,500 controls, thus emphasizing the need for greater statistical power. We increased power by expanding the controls, or 'reference set,' to include some or all of the other disease samples. When we did so, ARTS1 showed even stronger association evidence, the IL23R SNPs increased to a level that began to delineate them from background noise, and the AITD/ TSHR confirmation emerged. This demonstration of increased statistical power through the combination of multiple datasets is timely, given the international impetus to make genotype data available to the scientific community. Future investigations will be needed to assess the power versus confounding effects and the statistical corrections needed to combine more heterogeneous samples from broader sampling regions.
These results also highlight the question of how much information may be missed by focusing on coding SNPs rather than searching more broadly over the genome at large. This question is relevant because the tradeoff between SNP panel and sample size selection is a salient factor in the design of every genome-wide study. In the HapMap data 44 , a substantial portion of the common nonsynonymous variation in our nsSNP set is captured by available genomewide panels (about 65% of common (MAF 4 5%) nsSNPs in the Illumina Human NS-12 Beadchip are tagged with an r 2 4 0.8 using the Affymetrix 500 K chip, rising to 90% in the Illumina HumanHap300, which includes almost all of the nsSNPs from the NS-12 Beadchip). The four primary associated variants flagged in our study (that is, in ARTS1, IL23R, TSHR and FCRL3) would have been detected using any of the genome-wide panels, because either the markers themselves or a SNP in high LD with them (r 2 Z 0.78) are present on the genome-wide chips. This LD relationship also emphasizes the fact that observing an association with a nsSNP does not necessarily imply that the nsSNP is causal, as it may be indirectly associated with other genetic variants in or outside the gene. Given this high degree of overlap, the continuously increasing coverage of many available genotyping products and concomitant pressures to decrease assay costs, these data suggest that future gene-centric scans will be efficiently subsumed by the more encompassing and less hypothesis-driven genome-wide SNP panels.
METHODS
Subjects. Individuals included in the study were self-identified as white and of European ancestry and came from mainland UK (England, Scotland and Wales, but not Northern Ireland). The 1,500 control samples were from the British 1958 Birth Cohort (58C, also known as the National Child Development Study), which included all the births in England, Wales and Scotland that occurred during 1 week in 1958. Recruitment details and diagnostic criteria for each of the four case groups, as well as for the North American AS replication cohort and the 58C are further described in the Supplementary Methods online.
Sample quality assurance and control genome-wide identity by state (IBS) sharing was calculated for each pair of individuals in the combined sample of cohorts to identify first-and second-degree relatives whose data might contaminate the study. One subject from any pair of individuals who shared o400 genotypes IBS ¼ 0 and/or 480% alleles IBS (that is, the individual with the most missing genotypes) was removed from all subsequent analyses. To identify individuals who might have ancestries other than Western European, we merged each of our cohorts with the 60 western European (CEU) founder, 60 Nigerian (YRI) founder, and 90 Japanese (JPT) and Han Chinese (CHB) individuals from the International HapMap Project 44 . We calculated genomewide IBD distances for each pair of individuals (that is, 1 minus average IBS sharing) on those markers shared between HapMap and our nonsynonymous panel, and then used the multidimensional scaling option in R to generate a two dimensional plot based upon individuals' scores on the first two principal coordinates from this analysis (Supplementary Fig. 2 ). Any WTCCC sample that was not present in the main cluster with the CEU individuals was excluded from subsequent analyses. Finally, any individual with 410% of genotypes missing was removed from the analysis. The number of individuals remaining after these quality control measures were applied is shown in Table 1 .
Genotyping. We genotyped a total of 14,436 nsSNPs across the genome on all case and control samples. Because three of the diseases were of autoimmune etiology, we also typed an additional 897 SNPs within the MHC region, as well as 103 SNPs in pigmentation genes specifically designed to differentiate between population groups. SNP genotyping was performed with the Infinium I assay (Illumina), which is based on allele-specific primer extension (ASPE) and the use of a single fluorochrome. The assay requires B250 ng of genomic DNA, which is first subjected to a round of isothermal amplification that generates a 'high-complexity' representation of the genome with most loci represented at usable amounts. There are two allele-specific probes (50-mers) per SNP, each on a different bead type; each bead type is present on the array an average of 30 times (and a minimum of 5 times), allowing for multiple independent measurements. We processed six samples per array. Clustering was carried out with the GenCall software version 6.2.0.4, which assigns a quality score to each locus and an individual genotype confidence score that is based on the distance of a genotype from the center of the nearest cluster. First, we removed samples with more than 50% of loci having a quality score below 0.7 and then all loci with a quality score below 0.2. After clustering, we applied two additional filtering criteria: (i) we omitted individual genotypes with a genotype confidence score o0.15 and (ii) we removed any SNP for which more than 20% of samples had genotype confidence scores o0.15. The above criteria were designed to optimize genotype accuracy and minimize uncalled genotypes.
Statistical analysis markers that were monomorphic in both case and control samples, SNPs with 410% missing genotypes and SNPs with differences in the amount of missing data between cases and controls (P o 10 -4 as assessed by w 2 test) were excluded from all analyses involving that case group only. In addition, any marker that failed an exact test of Hardy-Weinberg equilibrium in controls (P o 10 -7 ) was excluded from all analyses 45 .
Cochran-Armitage tests for trend 46 were conducted using the PLINK program 47 . For the present analyses, we used the significance thresholds of P o 10 -4 -10 -6 , as suggested for gene-based scans with stronger prior probabilities than scans of anonymous markers 21 . In the present context, the lower thresholds are similar to Bonferroni significance levels (Bonferronicorrected P ¼ 0.05 corresponds to nominal P ¼ 3 Â 10 -6 ). The conditional logistic regression analyses involving the LNPEP and ARTS1 SNPs were carried out using Purcell's WHAP program 48 .
We manually rechecked the genotype calls of every nsSNP with an asymptotic significance level of P o 10 -3 by inspecting raw signal intensity values and their corresponding automated genotype calls. Notably, this flagged an additional 33 markers with clear problems in genotype calling, which were subsequently excluded from all analyses ( Supplementary Fig. 4 ). These results indicate that this genotyping platform generally yields highly accurate genotypes, but errors do occur and can be distributed nonrandomly between cases and controls despite stringent quality control procedures. It is imperative to check the clustering of the most significant SNPs to ensure that evidence for associations is not a result of genotyping error.
Although great lengths were taken to ensure that our samples were as homogenous as possible in terms of genetic ancestry, even subtle population substructure can substantially influence tests of association in large genomewide analyses involving thousands of individuals 49 . We therefore calculated the genomic-control inflation factor, l (ref. 20) , for each case-control sample as well as in the analyses where we combined the other case groups with the control individuals ( Table 2 ). In general, values for l were small (B1.1), indicating a small degree of substructure in UK samples that induces only a slight inflation of the test statistic under the null hypothesis, consistent with the results from our companion paper 12 . We therefore present uncorrected results in all analyses reported.
Consent was granted from ethical review boards of the institutions with which the participants were affiliated, and informed consent was obtained from the individuals involved in the WTCCC. Individual-level data from this study will be widely available through the Consortium's Data Access Committee (http://www.wtccc.org.uk).
Note: Supplementary information is available on the Nature Genetics website.
Rare, high-penetrance germline mutations in genes such as BRCA1 or BRCA2 account for less than 25% of the familial risk of breast cancer, and much of the remaining variation in genetic risk is likely to be explained by combinations of more common, lower-penetrance variants 1 . To date, case-control studies have generally focused on the investigation of putative functional candidate gene variants to attempt to identify low-penetrance susceptibility variants. However, individual studies often have only enough statistical power to detect effects of the order of 1.5 or more, depending on the frequency of the variant 2 , and thus collaborative studies are needed in order to achieve the sample sizes necessary to detect more modest effects. The Breast Cancer Association Consortium (BCAC) was established in 2005 to facilitate such collaborative studies in breast cancer. The consortium currently comprises over 20 international collaborating research groups, with a potential combined sample size of up to 30,000 cases and 30,000 controls. The first combined data analysis carried out by the consortium involved 16 SNPs that had been investigated in at least three independent studies with at least 10,000 genotyped subjects in total 3 . Members of the consortium then carried out further genotyping for four of these SNPs that showed borderline evidence of associations with risk: caspase-8 (CASP8) D302H (rs1045485), insulin-like growth factor binding protein 3 (IGFBP3) -202 C-A (rs2854744), manganese superoxide dismutase (SOD2 or MnSOD) V16A (rs1799725) and transforming growth factor beta (TGFB1) L10P (rs1982073), in order to confirm or refute these results. In addition, the BCAC examined five other SNPs for which there was published or unpublished evidence of an association: ataxia telangiectasia mutated (ATM) S49C (rs1800054) 4, 5 , class I alcohol dehydrogenase 1B (ADH1B, formerly called ADH2) 3¢UTR A-G (rs1042026) (P.D.P.P. et al., unpublished data), cyclin-dependent kinase inhibitor 1A (CDKN1A) S31R (rs1801270) (P.D.P.P. et al. and A.C. et al., unpublished data), intercellular adhesion molecule 5 (ICAM5) V301I (rs1056538) 6 and nuclear mitotic apparatus protein (NUMA1) A794G (rs3750913) 7 .
Details of the 20 studies contributing data to this report are shown in Supplementary Table 1 online. Apart from two studies in Asian populations, cases and controls were selected from populations of predominantly European ancestry, all with high breast cancer incidence rates (age-standardized rates ranging from 42.6 per 100,000 to 99.4 per 100,000 (ref. 8)) .
Two of the nine SNPs evaluated showed significant associations with invasive breast cancer: CASP8 D302H and TGFB1 L10P. Caspase-8 is an important initiator of apoptosis (programmed cell death) and is activated by external death signals and in response to DNA damage 9 . Two previous studies suggested that the D302H polymorphism in CASP8 (rs1045485), which results in an aspartic acid to histidine substitution, could reduce breast cancer risk 10, 11 .
Our analysis of 16,423 cases and 17,109 controls from 14 studies showed convincing evidence for a protective effect in an allele dose-dependent manner (P trend ¼ 1.1 Â 10 -7 , per allele odds ratio (OR) ¼ 0.88 (with 95% confidence interval (c.i.) of 0.84-0.92); Table 1 and Fig. 1a) . The result remained significant after excluding the initial positive result from the Sheffield Breast Cancer Study 10 (P trend ¼ 1 Â 10 -6 ), and there was no evidence of between-study heterogeneity (P ¼ 0.97). We found no evidence that the ORs varied © 2007 Nature Publishing Group http://www.nature.com/naturegenetics Table 1 Summary odds ratios and 95% confidence intervals for nine polymorphisms and breast cancer risk with age, estrogen receptor or progesterone receptor status, grade, stage or histopathological subtype ( Table 2 ). The ORs for ductal carcinoma in situ (DCIS) tumors were similar to that for invasive breast cancer. We saw no evidence of a stronger association in women with a history of breast cancer in first-degree female relatives, such as has been observed for other susceptibility alleles in ATM and CHEK2 (refs. 12,13) (per-allele OR for CASP8 D302H ¼ 0.87 (95% c.i.: 0.82-0.91), 0.98 (95% c.i.: 0.89-1.07) and 0.90 (95% c.i.: 0.79-1.01) for zero, one and two or more first-degree relatives, respectively). An association with family history would be expected under a polygenic model with multiplicative effects at different loci, and this result may therefore suggest a different pattern of interaction with other susceptibility alleles. Of note, this site was not polymorphic in Korean, Han Chinese or Japanese women (D.K. et al., unpublished data, http:// www.hapmap.org/). The functional consequences of the aspartic acidto-histidine substitution are not yet known, and further experiments are required to establish whether D302H itself, or another variant in strong linkage disequilibrium with it, is causative. Although this SNP was identified through a candidate gene approach, the association achieved a significance level close to that required for genomewide studies 14 .
Transforming growth factor-b (TGF-b) is a polypeptide cytokine that, inter alia, regulates normal mammary gland development and function by activating the TGF-b signaling pathway (reviewed in ref. 15 ). There is a dual-role model for the action of TGF-b in which it is thought to inhibit the development of early benign tumors, but once somatic oncogenic mutations have destroyed the normal tumor suppressor action of TGF-b, it then promotes tumor invasion and metastasis 15, 16 . Our analysis of the L10P variant (rs1982073) in the TGFB1 signal peptide showed a significant dosedependent association of the prolineencoding allele with increased risk of invasive breast cancer based on analyses of data from 11 studies comprising 12,946 cases and 15,109 controls (P trend ¼ 2.8 Â 10 -5 , per-allele OR ¼ 1.08, (95% c.i.: 1.04-1.11); Table 1 and Fig. 1b) . This result remained significant after exclusion of the initial result from the Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) 17 (P trend ¼ 8.0 Â 10 -4 ), with no evidence of betweenstudy heterogeneity (P ¼ 0.68).
The proline variant of TGFB1 has been associated with higher circulating levels of acid-activatable TGF-b 18 and increased rates of TGF-b secretion in in vitro transfection experiments 17 . From the dual-role model, it has been suggested that the proline (rapid TGF-b secretion) variant should be associated with a reduced risk of in situ tumors but an increased risk of invasive cancer. This study had insufficient cases with ductal carcinoma in situ (DCIS) to detect a significant differential risk (n ¼ 328), but the estimated ORs for DCIS were consistent with a protective effect ( Table 3) . As might be predicted by a polygenic model, the ORs were greatest in those under 40 and closer to unity in older age groups, although this trend was not significant at the P ¼ 0.05 level ( Table 3) . The ORs did not vary substantially by stage, grade or estrogen receptor status of the tumor. However, the significant association of the proline variant was confined to individuals with progesterone receptor-negative (rather than progesterone receptor-positive) tumors (P ¼ 0.017; Table 3 ).
The findings of previously published studies, which have not subsequently been subsumed into the BCAC, have been contradictory or null [19] [20] [21] [22] [23] [24] . A meta-analysis of the BCAC data together with the published studies (the latter totaling 4,021 cases and 8,253 controls) showed much weaker evidence for an increase in risk of the rare allele (per-allele OR ¼ 1.04 (95% c.i.: 1.01-1.07), P trend ¼ 0.012). Differences in case selection or characteristics between studies could contribute to the discrepancy with the published results. The BCAC data may be more reliable, as it should be less susceptible to any publication bias. However, despite the size of our study and the relatively high level of significance, we cannot rule out the possibility that the TGFB1 L10P association we found is a false positive result.
We observed borderline evidence of associations for two additional SNPs. The data suggest a recessive association for a promoter SNP in IGFBP3 (-202C-A, rs2854744), (OR ¼ 0.93 (95% c.i.: 0.87-0.99), P trend ¼ 0.046, Table 1 ). Two of the three previously published studies are included in the current analysis 25, 26 ; one previous null report is not included 27 . IGFBP3 is the principal binding protein regulating the activity of insulin-like growth factor 1 (IGF1), a circulating peptide hormone and growth factor for breast and other tissues. Odds ratio (95% CI)
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Odds ratio (95% CI) increased circulating IGFBP3 levels 27, 28 . However, the role of plasma IGFBP3 levels in breast cancer risk remains uncertain. Our data are consistent with the hypothesis that higher circulating levels of IGFBP3 are protective, but even the current large investigation has insufficient power to detect a recessive association with this allele at more than borderline levels of significance. ADH1B 3¢ UTR A-G (rs1042026) also yielded a borderline significant association (P ¼ 0.044). However, the heterozygote and homozygote genotypic associations were in opposite directions (Table 1) , they were not consistent across studies and they were not seen under the random effects model ( Table 1,  Supplementary Tables 2 and 3 online). Given that there is no biological rationale for such an observation, it is highly likely that the heterozygote association is due to chance. ATM S49C (rs1800054) was not significantly associated with overall breast cancer risk. However, the c.i. did not exclude a modest association, and this SNP increased the risk of progesterone receptor-positive breast cancer (OR ¼ 1.48 (95% c.i.: 1.08-2.04) under a dominant model (Supplementary Table 4 online). For the remaining four SNPs (CDKN1A S31R, ICAM5 V301I, SOD2 V16A and NUMA1 A794G), there was no evidence of an association with breast cancer ( Table 1 and Supplementary Fig. 1 online) . There was some evidence for heterogeneity between studies for CDKN1A S31R (P ¼ 0.009), NUMA1 A794G (P ¼ 0.029) and SOD2 V16A (P ¼ 0.016), but all ORs and 95% confidence intervals were virtually unchanged using a random effects model to allow for heterogeneity ( Table 1) . When we removed the only study of CDKN1A S31R in Asian women (International Agency for Research on Cancer-Thailand Study (IARC-Thai)), summary estimates from the remaining 14 studies in women of predominately European ancestry suggested a recessive association for this SNP (OR ¼ 1.37 (95% c.i.: 1.04-1.81) comparing rare homozygotes with common homozygotes; P ¼ 0.051). OR estimates for the other two SNPs were similar in the two studies in Asian countries, and we found no clear explanation for the observed heterogeneity. Confidence intervals for summary ORs, particularly from random effects models, did not exclude modest associations for these SNPs ( Table 1) . We did not observe any additional modification of genotype associations with breast cancer risk by age, estrogen receptor or progesterone receptor tumor status and did not find any significant associations for DCIS tumors (Supplementary Tables 4-7 online).
We estimate that the CASP8 D302H and TGFB1 L10P variants may account for approximately 0.3% and 0.2% of the excess familial risk of breast cancer, respectively, in populations of European ancestry. These data are the strongest evidence to date for common breast cancer susceptibility alleles, and they demonstrate the value of large consortia in identifying these variants.
METHODS
Subjects. Twenty breast cancer case-control studies contributed data to these analyses. A summary of the individual studies is given in Supplementary Table 1. All but two comprise subjects of predominantly European descent. Seven of the studies used population-based case ascertainment, nine ascertained cases from hospital-based series and one from a cohort. Five studies specifically included cases with a strong family history and/or bilateral cases. Table 3 online. We tested for heterogeneity between study strata by comparing logistic regression models with and without a genotype Â study interaction term using a likelihood ratio test. Data were also analyzed using a random-effects model to allow for heterogeneity.
We estimated category-specific risks by comparing the genotype distribution of cases and controls within each category (for age) or between each case category and all controls (for other variables) ( Tables 2 and 3 and Supplementary Tables 4-7) . To investigate the effects of age, subjects were separated into four categories (under 40, 40-49, 50-59 and 60+) according to age at diagnosis (cases) or interview (controls). Family history categories were (i) no family history of breast cancer, (ii) one first-degree relative with breast cancer and (iii) two or more first-degree relatives with breast cancers or bilateral breast cancer cases. Estrogen receptor and progesterone receptor status were categorized as positive or negative; tumor grade as 1, 2 or 3; and stage as I, II or III/IV. Histopathology categories were ductal and lobular. Individuals with DCIS were defined as not having had invasive breast cancer up to and including the time of diagnosis of DCIS. Category-specific data were not available for all subjects; the number of cases with data available for the relevant variables is indicated in Tables 2 and 3 and Supplementary Tables 4-7 .
We tested for interaction between genotype and other variables (age at diagnosis, family history, estrogen receptor status, progesterone receptor status, grade, stage and histopathological subtype) using a cases-only design. This approach is more powerful than standard case-control methods for detecting interaction 29 . Polytomous logistic regression was used to compare genotype frequencies in the different subgroups of each category stratified by study ( Tables 2 and 3 and Supplementary Tables 4-7) . The other variables and the number of rare alleles carried were fitted as ordinal covariates and a LRT (1 d.f.) then used to compare a model that included terms for genotype and study with a model including only a term for study.
The relative risk to daughters of an affected individual attributable to a given SNP was calculated using the formula where p is the population frequency of the minor allele, q ¼ 1 -p, and r 1 and r 2 are the relative risks (estimated as OR) for heterozygotes and rare homozygotes, relative to common homozygotes. The proportion of the familial risk attributable to the SNP was then calculated as log(l*)/log(l 0 ), where l 0 is the overall familial relative risk to offspring estimated from epidemiological studies (this formula assumes a multiplicative interaction between the SNP of interest and the other susceptibility alleles). l 0 was assumed to be 1.
(ref. 30).
A common coding variant in CASP8 is associated with breast cancer risk The affiliations of Angela Cox, Alison M. Dunning and Montserrat Garcia-Closas are incorrect in this PDF, but will be corrected soon.
The emerging landscape of breast cancer susceptibility
Michael R Stratton & Nazneen Rahman
The genetic basis of inherited predisposition to breast cancer has been assiduously investigated for the past two decades and has been the subject of several recent discoveries. Three reasonably well-defined classes of breast cancer susceptibility alleles with different levels of risk and prevalence in the population have become apparent: rare high-penetrance alleles, rare moderatepenetrance alleles and common low-penetrance alleles. The contribution of each component to breast cancer predisposition is still to be fully explored, as are the phenotypic characteristics of the cancers associated with them, the ways in which they interact, much of their biology and their clinical utility. These recent advances herald a new chapter in the exploration of susceptibility to breast cancer and are likely to provide insights relevant to other common, heterogeneous diseases.
In most Western populations, approximately one in ten women develop breast cancer. Epidemiological studies have shown that first-degree female relatives of women with breast cancer are at approximately twofold risk of developing the disease compared to the general population 1 . Although, in principle, this could be attributable to shared environmental or genetic factors, or both, twin studies indicate that most of the excess familial risk is due to inherited predisposition 2 .
Rare high-penetrance breast cancer susceptibility genes Major advances in understanding breast cancer susceptibility were made in the last decade of the twentieth century through genetic linkage mapping and positional cloning of two major predisposition genes, BRCA1 and BRCA2 (refs. 3-6) . Disease-causing variants in BRCA1 and BRCA2 confer a high risk of breast cancer, approximately 10-to 20-fold relative risk. This translates into a 30-60% risk by age 60, compared to 3% in the general population. The relative risks are higher for early-onset breast cancers, and there are also elevated risks of ovarian and other cancers 7, 8 . Disease-causing mutations in BRCA1 and BRCA2 result in inactivation of the encoded proteins, generally by causing premature protein truncation or nonsense-mediated RNA decay. There is population variation in mutation prevalence, but mutations are infrequent in most populations. Approximately 1 in 1,000 individuals in the UK are heterozygous mutation carriers of each gene, and there are numerous different mutations, each of which is very rare 9, 10 . Cancer predisposition is transmitted as an autosomal dominant trait in families harboring mutations. However, at the cellular level, BRCA1 and BRCA2 act as recessive cancer genes, with mutations converted to homozygosity in the cancers which they cause, usually through loss of the wild-type allele. Several years of biological investigation have firmly implicated BRCA1 and BRCA2 in doublestrand DNA break repair 11 . Mutations in BRCA1 and BRCA2 account for ∼16% of the familial risk of breast cancer 9, 10 . Germline mutations in TP53 cause Li-Fraumeni syndrome, which includes a high risk of breast and other cancers, but these mutations are very rare and hence account for a much smaller proportion of the familial risk. Cancer predisposition syndromes due to mutations in PTEN (Cowden syndrome), STK11 (Peutz-Jeghers syndrome) and CDH1 are also associated with elevated risks of breast cancer, although the cancer risks and prevalence of mutations in these genes are not well defined. It is unlikely that mutations in all six of these genes together account for more than 20% of the familial risk of the disease 12, 13 . Genome-wide linkage analyses using large numbers of families without mutations in BRCA1 or BRCA2 have not mapped additional susceptibility loci 14 . Although this does not completely exclude the existence of further high-penetrance breast cancer susceptibility genes, it strongly suggests that, if they exist, they account for a very small fraction of familial risk. So, how can the remaining ∼80% of the familial risk of breast cancer be explained?
A new harvest of breast cancer susceptibility alleles has recently emerged through two distinct strategies: direct interrogation of genes believed to be strong candidates, which has led to the identification of rare moderate-penetrance alleles [15] [16] [17] [18] [19] , and genome-wide tag SNP association studies, which have identified common low-penetrance alleles [20] [21] [22] (Box 1). We have considered these two new classes separately and in distinction to the rare high-penetrance genes discussed previously. It is possible that the differences among these classes may, at least in part, be attributable to the methods employed in their identification, and further discoveries may render the boundaries among them less distinct. Nevertheless, they currently provide a useful basis for considering the genetic landscape of breast cancer susceptibility.
Rare moderate-penetrance breast cancer susceptibility genes
The candidacy of the breast cancer susceptibility genes recently identified through direct interrogation for disease-causing mutations has been based primarily on involvement of the encoded proteins in biological pathways that include BRCA1 and BRCA2. To date, this strategy has identified at least four genes: CHEK2, ATM, BRIP1 and PALB2 (refs. 15-19) . CHEK2 is a checkpoint kinase involved in DNA repair that directly modulates the activities of p53 and BRCA1 by phosphorylation 23 . ATM also encodes a checkpoint kinase that has key functions in DNA repair, and which also phosphorylates p53 and BRCA1 (ref. 24) . BRIP1 (also known as BACH1) was discovered as a binding partner of BRCA1 and is implicated in some BRCA1 activities relating to DNA repair 25 . PALB2 was discovered as a protein associated with BRCA2 (ref. 26) . The patterns of susceptibility associated with these four genes have many features in common.
In CHEK2, ATM, BRIP1 and PALB2, most of the disease-causing mutations result in premature protein truncation or nonsense-mediated RNA decay through nonsense codons or translational frameshifts. A small proportion is likely to be rare missense variants that disrupt critical functions. In each of the four genes, there are multiple different pathogenic mutations, each of which is generally very rare. Diseasecausing mutations in each gene are found in less than 1% of the UK population: ∼0.6% are heterozygous carriers of CHEK2 mutations (a single mutation, CHEK2*1100delC, accounts for most of these), ∼0.4% are heterozygous carriers of ATM mutations and ∼0.1% or fewer are heterozygous carriers of BRIP1 or PALB2 mutations [15] [16] [17] [18] 27 . The prevalence of mutations in most other populations is currently less well characterized, although it is noteworthy that founder mutations in CHEK2 and PALB2 in Finland allowed independent identification of the association of these genes with breast cancer 19, 28 .
Overall, with respect to their effect on protein function, their prevalence in the population and their biological consequences, disease-causing mutations in CHEK2, ATM, BRIP1 and PALB2 bear many similarities to disease-causing mutations in BRCA1 and BRCA2. Where they differ is in the risks of breast cancer they confer. Although there is currently some imprecision in the risk estimates, it is clear that mutations in CHEK2, ATM, BRIP1 and PALB2 confer less elevated risks of breast cancer (about two-to threefold, with confidence intervals ranging from 1.2 to 3.9) than mutations in BRCA1 or BRCA2 (10-to 20-fold) [15] [16] [17] [18] 27 . Carriers of moderate-penetrance mutant alleles therefore have approximately a 6-10% risk of developing breast cancer by age 60, compared to ∼3% in the general population. For each gene, it is possible that there is risk heterogeneity, with some variants conferring greater risks than others (as is the case for BRCA1 and BRCA2 mutations), but there are currently few persuasive examples of this. Because CHEK2, ATM, BRIP1 and PALB2 mutations confer a smaller increased risk of breast cancer than BRCA1 and BRCA2 mutations, and their disease-causing mutations are uncommon, each of these moderate-risk genes makes a relatively small contribution to the overall familial risk of breast cancer. Current estimates suggest that mutations in the four genes together account for 2.3% of the familial risk of breast cancer, compared to 16% for BRCA1 and BRCA2 together 9,10,12,15 .
Features of rare moderate-penetrance susceptibility genes
Despite the many similarities of CHEK2, ATM, BRIP1 and PALB2 to BRCA1 and BRCA2, the lower breast cancer risk conferred by mutations in the former group leads to some uncomfortable departures from familiar genetic patterns. For example, in breast cancer-affected families carrying BRCA1 or BRCA2 mutations, the mutation and disease status usually track together, although even in this context the occasional sporadic 'phenocopy' is encountered. However, when the breast cancer risks associated with a particular allele are only two-to threefold, disease-causing mutations often do not segregate with the disease. This is because most mutation carriers do not actually develop breast cancer, because the sporadic rate of breast cancer is high, and because familial breast cancer clusters not associated with mutations in BRCA1 or BRCA2 probably reflect chance aggregations of susceptibility alleles in multiple different genes. As a consequence, segregation of the disease with the mutation, which is one of the tests a new disease susceptibility gene is routinely subjected to, is generally unhelpful for confirmation of lowerpenetrance alleles. If sufficient multiply sampled breast cancer-affected families with mutations are analyzed, it should be possible to formally show that the mutation segregates with the disease more frequently than Similarly, the familiar pattern of loss of the wild-type allele in cancers, which is generally associated with high-penetrance autosomal dominant cancer genes that operate in a recessive fashion in cancer cells, may be less apparent when sought in the context of lower-penetrance susceptibility alleles. Given the predominant pattern of inactivating disease-causing mutations, it is mechanistically plausible that CHEK2, ATM, BRIP1 and PALB2 behave in a fashion similar to BRCA1 and BRCA2 and show somatic loss of the wild-type allele in the cancers they cause. However, to demonstrate this pattern may require analysis of a substantial number of tumors, because only about half of breast cancers in individuals with a mutation in a cancer susceptibility gene conferring a twofold risk arise because of the mutation-the remainder would have occurred anyway. Allelic loss in cancers not due to the mutation will follow the pattern present in sporadic cancers for that locus, and will target the wild-type and mutant alleles equally. Thus, it may be necessary to analyze a large series of breast cancers from mutation carriers before meaningful, statistically robust data on loss of the wild-type allele can be obtained.
Elucidation of the phenotypes associated with heterozygous mutations in CHEK2, ATM, BRIP1 and PALB2 will also be hindered by the considerations discussed above, compounded by the rarity of diseasecausing alleles. At this stage, strong evidence does not exist for a higher risk of early-onset breast cancer, but most studies have had insufficient power to demonstrate it. The risks of other cancers, and the histological phenotypes of the breast cancers associated with mutations in these genes, are uncertain and may require large-scale collaborative initiatives to generate sufficient numbers.
Phenotypes associated with biallelic mutations
Mutations in high-and moderate-penetrance breast cancer genes confer an elevated risk of breast cancer in monoallelic (heterozygous) carriers. However, individuals with biallelic (homozygous or compound heterozygous) mutations in some of these genes have a different phenotype, often manifesting during childhood. This is exemplified by ATM, which was initially discovered by positional cloning of the gene underlying ataxia telangiectasia, an autosomal recessive condition characterized by loss of cerebellar Purkinje cells, immune deficiency and cancer predisposition 29 . Several epidemiological studies over the past two decades have shown that heterozygous (monoallelic) female carriers of ataxia telangiectasia-causing ATM mutations are at elevated risk of breast cancer, and molecular confirmation of this association was finally reported last year 17, 30 .
Similarly, in 2002, it was shown that biallelic BRCA2 mutations cause a rare subgroup of Fanconi anemia, subtype FA-D1 (ref. 31). Fanconi anemia is a genetically heterogeneous, recessive, chromosomal instability disorder characterized by growth retardation, skeletal abnormalities, bone marrow failure, cancer predisposition and cellular hypersensitivity to DNA cross-linking agents. FA-D1 is a distinctive subtype associated with severe disease and a high risk of childhood solid tumors such as Wilms tumor, medulloblastoma and glioma that occur rarely in classic Fanconi anemia 32 . Subsequently, it was shown that biallelic mutations in BRIP1 and PALB2 also cause rare subgroups of Fanconi anemia (FA-J and FA-N, respectively) [33] [34] [35] [36] . The phenotype of FA-N, resulting from biallelic PALB2 mutations, is characterized by severe disease and a high risk of childhood solid tumors and is virtually identical to that of FA-D1, presumably reflecting the close functional relationship between BRCA2 and PALB2 (refs. 32,34) . However, FA-J, caused by biallelic BRIP1 mutations, results in the classic Fanconi anemia phenotype and has not been associated with childhood solid tumors 33, 36 . It is possible that biallelic mutations in additional breast cancer susceptibility genes are responsible for other Fanconi anemia subtypes. However, both epidemiological and molecular analyses suggest that only a subset of Fanconi anemia genes are breast cancer susceptibility genes 37 . The factors that determine whether a Fanconi anemia gene is also a breast cancer predisposition gene are not known.
There is no known phenotype associated with biallelic mutations in CHEK2 or BRCA1. One individual homozygous for CHEK2*1100delC has been reported and was healthy until developing colorectal cancer at 52 years 38 . Conversely, although more than a decade has elapsed since BRCA1 was identified, no confirmed BRCA1 biallelic mutation carrier has been reported. It is conceivable that biallelic BRCA1 mutations cause a rare syndrome yet to be attributed to this gene, are embryonic lethal or (perhaps less likely) are not associated with any distinctive phenotype.
Common low-penetrance breast cancer susceptibility alleles A third component of the landscape of breast cancer susceptibility has been the subject of speculation for years, but has only just begun to surface. It is comprised of common alleles that confer very small increases in risk (common low-penetrance alleles). The currently known susceptibility alleles of this type have been discovered through association studies, either targeted at individual genes on the basis of biological candidacy or, more recently, through genome-wide tag SNP searches. In the past, numerous associations were proposed from targeted association studies involving relatively small numbers of cases and controls. Most of these have not been confirmed when evaluated on additional series, and such observations have acquired a certain notoriety and disrepute. Progress in this area of breast cancer research has depended, at least in part, on the formation of multigroup collaborations that combine data from very large numbers of cases and controls from many different locations and ethnic groups. These combined sets of tens of thousands of cases and controls provide substantial power to detect small effects and can obviate problems and limitations intrinsic to individual series 39 .
Only a small number of statistically unimpeachable, common lowpenetrance breast cancer susceptibility alleles have thus far been reported and confirmed in different populations [20] [21] [22] . For the purposes of this review, we focus on seven for which there is strong evidence and that can serve to illustrate at least the outlines of the emerging landscape [20] [21] [22] 40 . However, these are unlikely to represent all the patterns that will be found in future studies.
Five of the seven confirmed breast cancer risk alleles are within regions of linkage disequilibrium that cover known protein-coding genes. The genes in these regions include CASP8 (encoding caspase 8, a member of the cysteine-aspartic acid protease family whose sequential activation has a central role in the execution of apoptosis), FGFR2 (encoding fibroblast growth factor receptor 2), TNRC9 (recently renamed TOX3, encoding a protein with a putative high-mobility-group motif suggesting that it might act as a transcription factor), MAP3K1 (encoding mitogen-activated protein kinase kinase kinase 1, a protein likely involved in growth signaling) and LSP1 (encoding lymphocyte-specific protein 1, an intracellular F-actin binding protein). Some of these regions of linkage disequilibrium contain other genes, and it is conceivable that the functional associations are related to these rather than to the genes cited above, or perhaps to other, currently cryptic, genetic elements. Two of the seven susceptibility loci are on 8q and 2q, in regions with no known protein-coding genes [20] [21] [22] 40 .
The increased risks of breast cancer conferred by these seven susceptibility alleles are small. The relative risks of breast cancer associated with carrying a single copy of each risk allele range from 1.07 to 1.26, with the FGFR2 and 2q susceptibility alleles at the high end of this spectrum. The population prevalence of each risk allele is high, however, ranging from 28% to 87%. Interestingly, for some of these loci, the higher-riskallele is the more common. Because the predisposing alleles are common, despite the low risks they confer, their contribution to the familial risk of breast cancer is relatively substantial. The six loci characterized by Easton et al. and Cox et al. are estimated to account for 3.9% of the familial risk of breast cancer in European populations 20, 40 .
It is likely that there are very few, if any, additional common lowpenetrance susceptibility alleles that make contributions to the familial risk of breast cancer as substantial as those in FGFR2 or the locus on 2q. However, there is evidence for the existence of many, perhaps hundreds of, yet-to-be-discovered common susceptibility alleles with smaller effects 20 . Therefore, a sizeable proportion of the genetic architecture of breast cancer susceptibility may be embodied in a multitude of common susceptibility alleles, each of which accounts for a very small fraction of the familial risk.
Features of common low-penetrance susceptibility alleles
The disease-causing variants underlying these recently reported associations may not be easily identifiable, because the primary association is with a sentinel, reporter SNP that is often in tight linkage disequilibrium with many nearby variants. Even if the disease-causing variant is ultimately identified, it may not be obvious which gene(s) mediates its biological effects. Despite these complications and the limited number of common low-penetrance breast cancer susceptibility alleles thus far identified, some incipient trends and patterns may be emerging.
First, common low-penetrance breast cancer risk variants frequently reside in noncoding regions of the genome. For example, the susceptibility variant in FGFR2 is within an intron of the gene. Moreover, the susceptibility variants on 2q and 8q are both several tens of kilobases away from the nearest protein-coding genes. Of particular interest is the locus on 8q, which is in close proximity to different linkage disequilibrium blocks that contain alleles predisposing to prostate cancer and colorectal cancer [41] [42] [43] [44] [45] [46] [47] . It seems unlikely that this physical clustering is simply coincidence. Nevertheless, it remains to be seen whether these associations are mediated by a related biological mechanism.
Second, the mechanism of action of at least some common low-risk breast cancer-predisposing loci may be through activation of growthpromoting genes, in contrast to the inactivation of DNA repair genes that characterizes known rare high-and moderate-risk genes. For example, somatically acquired missense mutations, amplification and overexpression of FGFR2 are well documented in human cancer and result in overactivity of the protein 48, 49 . Furthermore, the gene closest to the breast, prostate and colorectal cancer risk variants on 8q, remarkably, is MYC, which is commonly amplified or overexpressed through chromosomal rearrangement in many types of cancer. Assuming that the predisposing variants at these loci are exerting their effects through FGFR2 and MYC (which is by no means certain), our current understanding of these genes would predict that the susceptibility alleles increase the activity of the encoded proteins. However, most of the currently mapped common low-penetrance loci are anonymous or have functions previously unrelated to cancer development, and they therefore may lead us into previously uncharted areas of cancer biology.
Third, in contrast to the rare high-penetrance and moderate-penetrance genes, homozygosity for a common low-penetrance susceptibility variant does not usually confer a distinct phenotype. Instead, homozygotes are phenotypically normal, but have an increased breast cancer risk that seems to be approximately the product of the risk for heterozygotes. Exploration of the histological phenotypes of cancers associated with common low-penetrance alleles is in its infancy, although at least some of these alleles seem to be particularly associated with estrogen receptor-positive breast cancers, in contrast to BRCA1 mutations, which are strongly associated with estrogen receptor-negative tumors 22, 50 .
Identification of further breast cancer susceptibility genes
The recent discoveries described here have together exposed a clearer picture of the genetic architecture of breast cancer susceptibility. BRCA1 and BRCA2 are likely to be the only major high-penetrance breast cancer susceptibility genes, and together with other rare, high-penetrance genes, they account for approximately 20% of the familial risk of disease. The remaining susceptibility is therefore due to genes conferring more modest increases in risk. CHEK2, ATM, BRIP1 and PALB2 are breast cancer susceptibility genes that bear many biological similarities to BRCA1 and BRCA2 but confer a breast cancer relative risk of two-to fourfold. They represent the current paradigms for a second class of rare moderate-penetrance risk alleles, but it would not be surprising if other such genes exist.
As disease-causing mutations in these genes do not generally result in large pedigrees with multiple breast cancer cases, further susceptibility genes of this class will not easily be mapped by genetic linkage analysis. Moreover, because the disease-causing alleles are uncommon, it is unlikely that they will be detected by association studies. Therefore, the most effective strategy to detect this class of gene is likely to remain the systematic screening of entire genes for potential disease-causing variants (usually truncating mutations) in series of breast cancer cases compared to controls. Because the breast cancer risks conferred by these variants are only two-to fourfold and the risk alleles are rare, the numbers of subjects required in these studies are large, rendering the analyses laborious by current technology. The problem can, to some extent, be mitigated by using familial rather than population-based breast cancer cases, as even lower-penetrance breast cancer susceptibility alleles are usually enriched in familial breast cancer cases compared to nonfamilial series. Use of population isolates with founder mutations of higher prevalence than is typical of outbred populations can also empower gene identification studies 19 . Such studies in Finnish breast cancer cases have provided suggestive data that RAD50 may be a moderatepenetrance breast cancer predisposition gene, although the rarity of truncating mutations precluded confirmation of an association with breast cancer in UK families 51, 52 . It is difficult to predict how many more rare moderate-penetrance genes exist, how much breast cancer susceptibility is accounted for by this component of the landscape or whether this pattern of susceptibility will extend beyond genes involved in DNA repair. Furthermore, the resequencing studies required for their identification are currently restricted to limited sets of candidate genes. However, with the likely advent of genome-wide resequencing of constitutional DNA, further exploration of this class of susceptibility allele should be possible.
Finally, the floodgates seem to be opening for the set of common lowpenetrance alleles that confer risks of 1.3-fold or less. Although the current state of knowledge is sketchy, we can at least now be sure that they exist and that they show biological differences from the rare high-penetrance and rare moderate-penetrance genes. Only a small proportion of the familial risk of breast cancer is thus far explained by well-supported examples of this class of susceptibility allele. However, it is possible that a substantial proportion of the still unexplained (>70%) familial risk may be due to large numbers of similar variants with smaller effects. Further studies should yield additional variants in this class, although even with existing large-scale collaborations, sufficient samples may not yet be available to conclusively identify many variants with weak effects.
Are there other areas of the landscape to be explored? An intriguing feature is the apparent discontinuity of breast cancer risks among the three currently defined groups of susceptibility alleles. Mutations in BRCA1 and BRCA2 confer 10-to 20-fold relative risks of breast cancer, the rare moderate-penetrance genes confer relative risks of 2-to 4-fold and the common low-penetrance alleles confer relative risks less than1.3-fold. Whether this pattern reflects a genuine biological stratification or an ascertainment artifact compounded by the limited number of known alleles remains to be seen.
It is also plausible that rare, nontruncating variants contribute to the genetic architecture of breast cancer susceptibility, given that rare truncating and common nontruncating variants are already known to be important. Investigating the role of rare nontruncating variants will, however, be challenging; their rarity will severely hamper detection through association studies, and it is very difficult to distinguish pathogenic nontruncating variants a priori from the plethora of innocuous rare variants.
Interactions between breast cancer susceptibility alleles
The available data suggest that many familial breast cancer clusters are likely to be due to the coincidence of multiple, lower-risk breast cancer susceptibility alleles 13, 53 . This raises the question of the manner in which each breast cancer susceptibility allele in such clusters interacts with the others. The evidence for the common low-penetrance variants seems to indicate that, in general, they interact with each other multiplicatively 20, 22 . Investigation of the breast cancer risks conferred by CHEK2*1100delC, however, showed that the pattern of multiplicative interaction does not always apply. Although CHEK2*1100delC confers an approximately twofold risk of breast cancer in most genetic backgrounds, it does not seem to confer an elevated breast cancer risk in carriers of BRCA1 or BRCA2 mutations 16 . Understanding that the proteins encoded by these genes lie in the same biological pathways provides a simple but credible explanation. In this example, abrogation of functions of these pathways by an inactivating mutation of BRCA1, BRCA2 or CHEK2 confers breast cancer susceptibility. However, if the relevant function is already abolished by a BRCA1 or BRCA2 mutation, an inactivating mutation in CHEK2 will not confer an additional breast cancer risk. Because CHEK2 is known to phosphorylate and regulate BRCA1 and is involved elsewhere in double-strand DNA break repair, this notion has a reasonably solid foundation in our current understanding of these pathways 11, 23 .
It is currently unknown how common susceptibility alleles interact with rare susceptibility variants, though it is likely that relevant data will be forthcoming in the near future. Exploration of interactions among breast cancer risk alleles and nongenetic factors, such as hormonal profiles and environmental exposures, is also in its infancy, and will be vital in building a comprehensive picture of the underlying causes of familial clustering of the disease.
Clinical utility
Diagnostic testing for mutations in BRCA1 and BRCA2 has been routine clinical practice in many countries for several years. It facilitates risk estimation and implementation of cancer prevention strategies and increasingly has the potential to influence cancer therapy 54, 55 . Management interventions in breast cancer-affected families without BRCA1 or BRCA2 mutations have inevitably been more limited, as less information has been available for risk evaluation. The identification of new susceptibility alleles may offer the potential for improved care in such families: for example, if combinations of alleles alter the risk category of an individual such that screening or prophylactic interventions might be considered. However, clinical testing of the new generation of susceptibility genes will need to be undertaken carefully and cautiously, and more detailed information on the associated risks and interactions will first be required. Implementing routine testing of a large number of different susceptibility alleles in a substantial set of genes will also require careful deliberation, as it may generate considerable technical and economic burdens for clinical diagnostic services.
Future challenges
These recent advances have underscored the complexity of breast cancer susceptibility, revealing at least three different strata in the genetic architecture of the disease: rare high-penetrance alleles, rare moderate-penetrance alleles and common low-penetrance alleles. It is likely that these categories of susceptibility alleles are germane to many other complex conditions. However, their exploration remains demanding, particularly as the identification of alleles underlying each class requires different strategies and technologies. Moreover, despite the remarkable progress made in the last year, most of the familial risk of breast cancer remains unexplained, highlighting the need for ongoing efforts to expand our view of the emerging landscape of breast cancer susceptibility.
